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CHAPTER I 
 
INTRODUCTION 
 
Cystic Fibrosis 
 
Disease History and Overview 
 Cystic fibrosis is the most common genetic disorder in white 
populations, affecting 1 in 2500 live births. It was first described in 1938 as 
“cystic fibrosis of the pancreas”, after autopsy studies of malnourished infants 
uncovered mucus plugging in glandular ducts1. The term “mucoviscidosis” was 
used as an alternative description of this disease in 1944, due to the 
accumulation of thick viscous that plugged the ducts of mucus glands2. Soon 
after, CF was considered to be a genetic disorder caused by a defect in a 
single gene because of its autosomal recessive pattern of inheritance3. The 
discovery of defective sweat sodium and chloride balance meant that the basic 
defect of the disease was not a disorder of mucus production4. In 1983, 
defective chloride transport accompanied by increased sodium reabsorption 
was identified as the main culprit in the development of CF5. This was verified 
by the discovery of the CF gene in 1989, which encoded a chloride channel 
named the cystic fibrosis transmembrane conductance regulator (CFTR)6. 
When CF was first described in 1938, the life expectancy of a CF patient was 
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around 6 months2. However, with the advancement in therapy and care, the 
life expectancy has risen to 37 years of age in the United States7.    
 
CFTR 
 CFTR is an ion channel and a member of the ATP-binding cassette 
(ABC) superfamily that is widely expressed at the apical side of epithelial 
cells8. It consists of two membrane-spanning domains (MSD) with six 
transmembrane helices each, two nucleotide-binding domains (NBD), and a 
regulatory domain (RD)9. CFTR is regulated by cAMP-dependent 
phosphorylation of RD by protein kinase A (PKA), which allows ATP binding to 
NBD1 and NBD2 and the consequent dimerization of the two domains to form 
a pore that allows for ion movement across the channel10.   
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CFTR Mutation Classes 
 Since the discovery that CF is caused by mutations in the gene 
encoding CFTR, there have been close to 2000 identified mutations11. 
Mutations fall into six classes based on the general mechanism of CFTR 
dysfunction10: 
• Class I mutations, defective protein production: These are nonsense, 
frame shift and splicing mutations that lead to premature transcription 
termination causing defective protein synthesis.  
• Class II mutations, defective protein processing: the missense 
mutations in this class disrupt the protein folding and trafficking to the 
apical membrane.  
• Class III mutations, defective channel regulation: Mutated CFTR 
protein is produced, processed and delivered properly to the cell 
membrane. However, the regulation of the channel is disrupted so that 
it no longer opens in response to channel agonists.  
• Class IV mutations, defective channel conduction: like class III 
mutations, CFTR in this class is delivered correctly to the membrane; 
however, the mutations produce a misshaped channel pore that 
restricts ion movement.  
• Class V mutations, reduced protein synthesis: CFTR protein produced 
by this class of mutations is produced at extremely reduced levels 
resulting in less protein at the cell membrane.  
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• Class VI mutations, reduced protein stability: although CFTR reaches 
the membrane, mutations of this class cause a reduction in protein 
stability and increase its turnover, which results in low CFTR levels. 
 
A phenylalanine deletion at position 508 (ΔF508) causes the most 
common CFTR mutation7. Nearly 90% of CF patients carry at least one copy 
of this mutation11. ΔF508 is considered a class II mutation, where the protein 
is misfolded and tagged for degradation without reaching the membrane. 
However, it is a complex mutation that has characteristics of Classes III and VI 
in that even if the protein reaches the membrane it will have a gating defect 
and will be unstable11. Class I and class III mutations account for 7% and 3% 
of all CF mutations, respectively. Classes I, II, and III cause a complete loss of 
CFTR function and are considered severe, whereas, classes IV, V, and VI 
allow residual ion transport and are therefore viewed as mild mutations7.       
  
CF Disease Phenotype and Pathogenesis  
 The loss of CFTR function causes a defect in Cl- reabsorption by 
epithelial cells in the reabsorptive duct in the sweat glands, which leads to high 
salt concentrations in the sweat of CF patients12. This disease feature has 
been used reliably as a diagnostic test for CF13. CFTR interacts both directly 
and indirectly with many proteins in the cell14. The epithelial sodium channel 
(ENaC) is responsible for sodium movement across membranes in the 
opposite direction of Cl-. Importantly, it is one of the proteins that are affected 
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by CFTR15. In this setting CFTR activation inhibits the activity of ENaC and 
prohibits the movement of Na+. Therefore, with the loss of CFTR function, 
ENaC is no longer restricted, and sodium flow is increased into the cell. This 
influx of sodium into the cell is followed by water, which decreases liquid 
volume in the lumen16, leading to the development of thick viscous mucus that 
can lead to various organ dysfunctions17. The main organs affected in CF are 
the lungs, pancreas, GI tract, and the male reproductive system. In the GI tract 
the accumulation of thick mucus causes intestinal obstruction and lead to 
malabsorption. Meconium ileus is present in 15% of neonates, which if left 
untreated is lethal.  
The fat and protein malabsorption is exacerbated by pancreatic 
dysfunction in CF10. In this organ, the presence of thick dehydrated mucus 
leads to plugging of the pancreatic ducts and has two major consequences7. 
First, it prohibits the delivery of pancreatic enzymes to the duodenum and 
therefore the digestion of lipids and proteins is halted and will lead to 
malnutrition. Second, the trapped enzymes will cause inflammation and 
autolysis of the exocrine pancreas and its eventual replacement by fat. This 
leads to pancreatic insufficiency (PI) in almost 90% of CF infants, which is 
characterized by greasy stools, flatulence, abdominal bloating, and most 
notably, poor weight gain. PI can be present at birth or may develop and 
progress over the first year of birth. Males with CF are infertile due to 
congenital bilateral absence of the vas deferens, which is extremely sensitive 
to CFTR dysfunction. Increased water reabsorption in the lungs of CF patients 
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causes mucus plugging and a significant decrease in the airway surface liquid 
(ASL) volume, which leads to impaired mucocilliary action and chronic 
infection and inflammation17.     
 
Cell Culture and Animal Models of CF 
 Several immortalized cell models of CF have been developed from 
tissues important in CF pathology from both CF and non-CF individuals. While 
there are pancreatic-derived cell models, like CFPAC-1 cells, most of the 
developed cell models are derived from lung epithelial cells, such as IB3-1, 
CFBE45o-, and 16HBE14o-. 18. To further our understanding of the complex 
mechanisms of CF disease in humans, mouse models of this disease were 
developed. Several mouse models of CF have been developed and 
extensively used over the past two decades, such as the CFTRtm1UNC 19. While 
CF mouse models have provided valuable insights in CF pathology, they lack 
some of the important abnormalities that CF patients develop early in life in 
organs such as the lungs and pancreas. This has led to the development of 
pig and ferret models of CF, which develop most of the defect seen in CF 
patients, including predisposition to lung disease20,21.   
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Lung Inflammation in Cystic Fibrosis 
The main cause of morbidity and mortality in CF is progressive 
pulmonary failure that is characterized by a vicious cycle of obstruction, 
infection, and inflammation, which leads to tissue destruction (Fig 1). As stated 
above, defective CFTR function in the lungs compromises mucociliary 
clearance, causing obstruction of respiratory passages by thick, viscid mucus, 
which leads to luminal dilation in the submucosal glands22. This creates a 
suitable environment for non-resolving infections, since pathogens clearance 
is defective23. Pseudomonas aeruginosa is the major bacterial pathogen in CF 
airways24. By the time CF patients reach middle teenage years, most are 
infected with Pseudomonas and will subsequently never be free of this 
pathogen. This is due to the manner by which Pseudomonas adapts to the CF 
airway microenvironment whereby it produces copious amounts of 
extracellular capsular polysaccharides that gives the bacteria a mucoid 
appearance and indicates the formation of a biofilm25. The development of this 
phenotype signals an accelerated decline in lung function as it protects the 
bacteria from host defenses and leads to the formation of immune complexes 
around the biofilm, which in-turn exacerbates the inflammatory response26.  
Enhanced inflammation appears to play a significant role in CF 
pathophysiology. The airway epithelium contributes significantly to the 
inflammatory response by producing a variety of molecules that aid in 
recruiting immune cells27. Infected CF airways exhibit marked inflammation, 
characterized by profuse neutrophil infiltration and production of pro-
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inflammatory oxygenated fatty acid metabolites and cytokines, such as 
leukotriene B4 (LTB4) and interleukin (IL)-1β, IL-6, and IL-828. Recruited 
neutrophils, in turn, elicit more release of pro-inflammatory mediators and lead 
to a further increase in the perpetuating inflammatory cycle.  
While chronic bacterial infections are the leading cause for neutrophilic 
inflammation in CF lungs, there may be other possible contributing factors26. 
First, the inflammatory response in CF could be disproportionate to levels of 
infection. A study that investigated the inflammatory response in CF mice after 
intrabronchial instillation of PA agarose beads showed that CF mice had a 
higher mortality rate. In addition, they had a greater concentration of several 
inflammatory mediators in their BAL fluids in response to the same bacterial 
load as their WT littermates29. Second, the airway epithelium may be 
inherently pro-inflammatory and the inflammatory response may be increased 
even in the absence of infection. Several studies have evidence to support this 
theory. Using a human fetal tracheal graft in-vivo model30, Tirouvanziam et al. 
showed that uninfected CF airway grafts, but not matched WT controls, 
underwent neutrophil-driven inflammation that led to lung tissue destruction. 
Moreover, several studies reported the presence of inflammation independent 
of the presence of pathogens in the lungs of children that are 15 months or 
younger31, infants 6-months of age32, even in the lungs of a CF fetus33.  These 
findings imply that CFTR mutations may establish a uniquely pro-inflammatory 
state, although the mechanisms are poorly understood. 
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Figure 1:  
Lung disease is the main cause of mortality in CF. Lung disease in CF is 
characterized by a vicious cycle of mucus plugging, chronic infections, and 
non-relenting neutrophilic inflammation.  
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Fatty Acids and Their Oxygenated Metabolites in CF 
Fatty Acids 
 A fatty acid is comprised of an aliphatic carbon chain, that can be 
saturated or unsaturated, connected to a carboxylic group. The term 
polyunsaturated fatty acid (PUFA) is used to describe any fatty acid with 2 or 
more double bonds. Unsaturated fatty acids fall into four major groups based 
on the position of the last double bond from the methyl end. These groups are 
n-3, n-6, n-7, and n-9, where the last double bond in each group is 3 carbons, 
6 carbons, 7 carbons, or 9 carbons away from the methyl end, respectively. 
While n-7 and n-9 fatty acids can be synthesized de-novo, n-3 and n-6 fatty 
PUFAs are essential fatty acids (EFA), in that mammals cannot synthesize 
them and must obtain them from dietary sources34.  
Palmitic acid (16:0) can be the precursor of both the n-7 and the n-9 
pathways, where its chain length and desaturation is increased by the actions 
of elongase and desaturase enzymes (Fig 2). Elongase enzymes add two 
carbons, while desaturase enzymes remove two hydrogens and introduce a 
double bond to the fatty acid. Alpha linolenic acid (LNA, 18:3n-6) and linoleic 
acid (LA, 18:2n-6) are the precursor fatty acids in the n-3 and the n-6 
pathways, respectively. Both LNA and LA are converted to their downstream 
PUFA in the n-3 and n-6 pathways via a series desaturation and elongation 
followed by a final peroxisomal β-oxidation step (Fig 3). EFA dietary intake 
levels have great implications in the inflammatory process. In particular, the 
intake of n-6 PUFA increases the availability of arachidonic acid (AA, 20:4n-6) 
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in cell membranes and may exacerbate inflammatory diseases by the 
production of oxygenated metabolites, which play a significant role in 
inflammation35. Since both the n-3 and n-6 pathways compete for the same 
desaturase and elongase enzymes, the dietary intake ratio of n-6/n-3 PUFA 
can determine the dominance of each pathway. Historic n-6 to n-3 ratio used 
to be close to 1:1. However, as the human diet changed this ratio has risen 
dramatically to be closer to 20:136. Many disorders such as cardiovascular 
disease, inflammatory and autoimmune disorders have been shown to be 
enhanced by a high n-6/n-3 ratio, while they were suppressed when that ratio 
is decreased37.  
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Figure 2:  
The n-7 and n-9 biosynthesis pathways. 
 
 
 
 
 
 
 
	  	  
	  
13	  
 
 
 
 
 
 
Figure 3:  
The n-6 and n-3 biosynthesis pathways. 
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Oxygenated Metabolites of Fatty Acids 
 While a small fraction of fatty acids occur as free fatty acids, the 
majority are esterified to form cholesterol esters, triglycerides, or 
phospholipids. The latter is usually the most abundant component of cell 
membranes38. Phospholipase A2 (PLA2) is the enzyme responsible for 
hydrolyzing the fatty acid from the sn-2 position in membrane phospholipids, 
which is most frequently occupied by PUFAs, such as AA. PLA2 enzymes fall 
into three main categories: cytosolic PLA2 (cPLA2), which has a high 
molecular weight and depends on micromolar intracellular calcium 
concentrations, secretory PLA2 (sPLA2) which is stored in granules and 
secreted upon activation, has a low molecular weight, and depends on 
millimolar calcium concentrations for activation, and calcium-independent 
PLA2 (iPLA2), which is present in the cytosol and membrane fractions39. The 
enzymatic action of cPLA2 appears to play a pivotal role in the inflammatory 
process, as it is the only phospholipase that preferentially hydrolyzes sn-2 
bound AA upon inflammatory stimulation40.  
The importance of cPLA2 relates to the formation of eicosanoids, which 
are oxygenated metabolites that are produced from 20-carbon PUFAs, with 
AA as the major substrate. Once AA is released from membrane 
phospholipids by cPLA2, it is rapidly converted to a variety of metabolites 
mainly via the enzymatic actions of cyclooxygenase (COX) and lipoxygenase 
(LOX) pathways (Figs 4,5). AA can be converted into a variety of eicosanoids 
via the cyclooxygenase pathway that has two main isoforms COX-1 and COX-
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2. While COX-1 is constitutive and is ubiquitously expressed, COX-2 is 
inducible and is expressed in response to stimulation and inflammation. These 
enzymes convert AA to the unstable intermediate prostaglandin (PG) H2, 
which in turn is converted to the biologically active prostanoids PGE2, PGD2, 
PGF2α, PGI2, and thromboxane (TX) A2 by specific synthases41. There are 
three distinct isoforms of the PGE2 synthases (PGES): cytosolic (cPGES), 
microsomal (mPGES-1) and mPGES-2. Of those enzymes mPGES-1 is an 
inducible isoform that is associated with COX-2 and inflammation42. 
Lipoxygenase enzymes are classified as 5-, 12, or 15-LOX based on 
the position of oxygen insertoin in AA. Leukotriene A4 (LTA4) is produced from 
AA via the enzymatic action of 5-LOX, which requires Ca2+ for activation, 
aided by the 5-LOX activating protein (FLAP), which is an accessory protein 
that binds to the AA released by PLA2. LTA4-hydrolase (LTA4H) can convert 
this unstable intermediate to LTB4, which is a very potent neutrophil 
chemoattractant. Alternatively, LTA4 can be conjugated with glutathione (GSH) 
by LTC4 synthase (LTC4S) to form LTC4, which can be metabolized into LTD4 
and LTE4. LTC4, LTD4, and LTE4 are called cyteinyl LTs (cysLT) because of 
their similar structures and biological functions, as they are involved in both 
bronchoconstriction and vasoconstriction43.  
Another important class of AA-derived eicosanoids is lipoxins (LX), 
which have anti-inflammatory properties such as inhibiting neutrophil 
trafficking and promoting macrophage phagocytic actions of apoptotic 
neutrophils, are produced by two different LOX enzymes that usually come 
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from two different cell types during cell-cell interactions. For example, AA can 
be converted to 15-hydroxyeicosatetraenoic acid (HETE) by 15-LOX in 
epithelial cells, which can then be converted by 5-LOX from infiltrating 
neutrophils to form LXA444.  
Eicosanoids usually signal, in both autocrine and paracrine fashion, via 
G protein—coupled receptors (GPCR). PGE2, PGD2, PGF2α, PGI2, and TXA2 
signal through E prostanoid (P), DP, FP, IP, and TP, respectively. There are 
four subtypes of the PGE2 receptor that differ based on their GPCR signaling. 
EP1 signals through Gq and increases free Ca2+, EP3 signals through Gi and 
inhibits adenylate cyclase, and finally, EP2 and EP4 signal through Gs and 
increase cAMP concentrations. Similarly, leukotriens signal through GPCRs. 
LTB4 signals through BLT1 or BLT2, while LTC4, LTE4, and LTD4 signal 
through cysLT1 or cysLT245.  
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Figure 4: 
AA-derived eicosanoid production through the COX pathway.  
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Figure 5: 
AA-derived eicosanoid production through the 5-LOX pathways. 
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PUFAs from the n-3 family can also be converted to oxygenated 
metabolites (Fig 6). EPA is a 20-carbon n-3 PUFA that can compete with AA 
for both phospholipid presence and enzymatic action of COX and LOX 
pathways, by which it can be converted to 3-series prostanoids and 5-series 
leukotrienes. These oxygenated products are similar to the ones derived from 
AA; however, they are far less potent. Additionally, both EPA and DHA can be 
converted to anti-inflammatory oxygenated metabolites by the action of 
various LOX enzymes or acetylated COX-2. EPA can be converted to 
“resolution-phase interaction products” or resolvins of the E-series (RvE), 
whereas, DHA can be converted to D-series resolvins (RvD), neuroprotectins 
(NPD), and “macrophage mediators in resolving inflammation” or maresins 
(MaR)46.    
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Figure 6:  
The common production pathways of n-3 PUFA-derived oxygenated 
metabolites.  
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Role of Fatty Acid Oxygenated Metabolites in Inflammation  
 Temporal production of PUFA-derived lipid mediators plays an 
important role in the initiation and resolution of inflammatory events. The 
introduction of an insult to tissue, such as bacterial infection, elicits the 
production and release of AA-derived eicosanoids as a part of the 
inflammatory response. Release of LTB4 at the initial stages of inflammation 
enhances chemoattractant signals and leads to augmented neutrophil 
recruitment, while the production of PGE2 increases blood flow and vessel 
permeability to allow for leukocyte migration to the site of insult. As 
inflammation progresses, several events initiate the signal for inflammatory 
resolution47. Oxygenated metabolites contribute significantly to this process 
via their “class switching” ability, by which the production of proinflammatory 
metabolites is decreased and the production of pro-resolving metabolites is 
initiated48. In particular, PGE2 has been shown to have the ability to trigger this 
“class switching” event by inhibiting the expression of 5-LOX and inducing the 
expression of 15-LOX, which decreases LTB4 while increasing LXA4, and 
leads to inhibition of neutrophil recruitment and the eventual resolution of 
inflammation. This resolution phase is further enhanced by the production of n-
3 PUFA-derived anti-inflammatory mediators, such as RvE, RvD, NPD, and 
MaR44.  
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PUFA Alterations in CF 
 Fatty acid abnormalities in the blood and tissue of CF patients were first 
reported in 196249. Since then, consistent PUFA alterations, mainly decreased 
LA and DHA levels and changes in AA metabolism, have been associated with 
CF. Many studies have examined fatty acid levels in serum, plasma, 
erythrocytes, and whole blood samples from CF patients50-67. Decreased LA 
levels were reported in all of those studies, while decreased DHA and 
increased palmitoleic acid (POA, 16:1n-7) and mead acid (MA, 20:3n-9) in CF 
patients were observed in the majority of those studies. On the other hand, AA 
was either unchanged or found to be decreased in the blood of CF patients in 
a minority of studies. Similar findings have been shown in other tissues from 
CF patients. LA and DHA levels were decreased in the nasal and rectal 
biopsies of CF patients63. AA levels were significantly higher in the nasal 
biopsies of CF patients in this study, and was similarly increased in the BAL 
fluid of CF patients in a different study68. These alterations were also found in 
animal and cell culture models of the disease. In both CFTR KO and ΔF508 
CF mouse models, investigators found decreased LA and increased AA levels 
in multiple tissues, including the small intestines, pancreas, and lungs.  
These alterations were observed in CF airway epithelial cells as 
well69,70. Importantly, studies suggest that these alterations were due to an 
increased expression and activity of specific metabolic enzymes involved in 
fatty acid metabolism. Radiolabeled studies showed that the decreased LA 
levels are attributed to an increased flux in the n-6 pathway, driven by an 
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increased expression of the rate-limiting enzyme Δ6-desaturase in addition to 
Δ5-desaturase71. Similar radiolabeled studies demonstrated that the increased 
POA and MA levels in the n-7 and n-9 pathways is due to increased flux in 
these pathways. This increased metabolism was dependent on higher 
expression of Δ9-desaturase and elongase-6 in addition to Δ5D and Δ6D72. 
The mechanism behind low DHA levels in CF is less clear. Radiolabeling 
studies have shown that the flux of eicosapentaenoic acid (EPA, 20:5n-3) to 
DHA is decreased in CF cells, while the flux of docosapentaenoic acid (DPA, 
22:5n-3) to DHA appeared to be the same in both CF and WT cells71. This 
suggests that there could be a defect in the elongation step between EPA and 
DPA in the n-3 pathway. Alternatively, EPA might be shunted into another 
pathway, such as eicosanoid production, rendering it unavailable for 
metabolism to DHA. Another possible mechanism involves the retroconversion 
of DHA back to EPA via modified peroxisomal β-oxidation73-75. While 
assessing this pathway is technically challenging, its activity may be estimated 
by comparing EPA and DHA levels after DHA supplementation. Using this 
method in an airway epithelial cell model, CF cells showed a 20 times higher 
rate of retroconversion compared to WT cells, which may account for the lower 
DHA levels71. Additional studies are required to elucidate the retroconversion 
pathway and its contribution to the fatty acid abnormalities in CF.  
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Significance of Fatty Acid Alterations in CF 
 PUFA alterations in CF were thought to be secondary to pancreatic 
insufficiency and malabsorption. However, there are several reports that 
proved otherwise. A study by Rogiers et al. showed that LA levels were 
decreased in both free fatty acid and cholesterol ester fractions, independent 
of pancreatic status in CF patients58. Moreover, persistent PUFA alterations 
were not corrected in CF patients with malabsorption adequately treated by 
nutritional supplementation or pancreatic enzyme replacement62,65. In fact, 
these alterations were recapitulated in airway epithelial cell culture models of 
CF, which provides further evidence that these alterations are part of an 
intrinsic defect in CF not related to lipid digestion or absorption69,71. Moreover, 
the consistent nature of these alterations may suggest they are not merely 
phenomenological, but rather may play a significant role in the 
pathophysiology of this devastating disease. This is supported by studies that 
examined correlations between PUFA alterations and disease status of CF 
patients. A report by Strandvik et al. found that LA levels were significantly 
lower in patients with severe mutations, while patients with mild mutations had 
LA levels comparable to levels observed from normal controls52.  Van Biervliet 
et al. reported similar findings regarding lower LA levels in CF patients with 
severe mutations, in addition to higher 20:3n-6, 22:5n-6, and MA, when 
compared with patients that have moderate mutations76. Additionally, these 
PUFA alterations were found in both patients homozygous for CFTR mutations 
and their heterozygous parents, albeit they were more pronounced in the 
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homozygous group51. Furthermore, PUFA alterations correlated with the 
clinical status54, and pulmonary function of CF patients60,77. Interestingly, 
inhibiting Cl- conductance by chloride channel blocker anthracene 9-
carboxylate in primary airway epithelial cell significantly lowered LA levels78.  
 PUFA are important constituents of membranes, where they may play 
an important role in both membrane structure and direct protein interaction. 
Therefore, PUFA alterations may influence CF pathophysiology by changing 
membrane composition or regulating membrane-associated proteins. In 
support of this hypothesis, there have been studies that looked at the effect of 
AA on Cl- conductance by CFTR. Linsdell et al. demonstrated by using patch 
clamp recordings from CFTR-transfected baby hamster kidney cells that, when 
applied to the cytoplasmic side of the excised membrane patches, AA is able 
to inhibit CFTR Cl- conductance79. On the other hand, Li et al. showed that AA 
has a dual regulatory effect on CFTR Cl- conductance in airway cells, where it 
inhibits the conductance in excised membrane patches, but stimulates 
conductance in intact cell monolayers80. This implicates AA as a regulator of 
CFTR, which may offer a partial explanation for the observed PUFA 
alterations. 
 PUFA are precursors of many biologically active oxygenated 
metabolites that play a significant role in inflammation. As mentioned above, 
there is plenty of evidence that implicates inflammatory dysregulation in the 
pathogenesis of CF. PUFA alterations in CF may affect pathophysiology via 
the dysregulated production of oxygenated metabolites. Of those metabolites, 
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AA-derived eicosanoids have a profound part in driving the inflammatory 
response. This may implicate specific PUFA alterations in the inflammatory 
response in CF. In particular, the decreased LA and variably increased AA 
levels that have been attributed to increased metabolism from LA to AA in CF 
cells. This increased metabolism leads to increased availability of AA for the 
production of proinflammatory eicosanoids.  
Since AA release from membrane phospholipids by PLA2 is the rate-
limiting step in eicosanoid production, studies have investigated the effect of 
CFTR dysfunction on this crucial step. Calstedt-Duke et al.81 and Miele et al.82 
reported increased AA release in lymphocytes from CF patients and in a CF 
epithelial cell line carrying a ΔF508 mutation, respectively. The increase in AA 
production and release is accompanied by significant evidence of higher 
production of proinflammatory eicosanoids in CF.  
Several studies reported increases in both prostaglandins, particularly 
PGE2 PGF2α and their metabolites71,83-88, and leukotrienes71,89,90 in CF 
patients and models of disease. Expression of both COX and LOX enzymes 
was also augmented in patient tissues and cell models71,88,91,92. The levels of 
these eicosanoids correlated with disease severity83,87,93, and were shown to 
be associated with acute pulmonary exacerbations94. In contrast, anti-
inflammatory LXA4 levels have been shown to be significantly suppressed in 
airway fluid of CF patients95. Moreover, it was shown that administration of a 
stable LXA4 analog was able to decrease bacterial burden, suppress 
neutrophilic inflammation, and attenuate lung disease severity, in a mouse 
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model of chronic lung infection and inflammation associated with CF95. This 
may be suggestive of defective inflammation resolution in CF. Importantly, it 
may also implicate low DHA levels in the pathophysiology of CF, since it is a 
precursor of a variety of oxygenated metabolites heavily involved in 
inflammation resolution. In support of this, Freedman et al. demonstrated, 
using a CFTR-/- knockout mouse model, that DHA administration reversed the 
characteristic PUFA alterations, alleviated disease pathology in the GI tract 
and pancreas, and significantly reduced neutrophilic inflammation in the lungs 
of CF mice96.   
 
Therapeutic Potential of PUFA 
 DHA has been shown to have the ability to reverse the observed PUFA 
alterations in both airway epithelial cell culture70,97 and lungs of animal96,98 
models of CF. These studies, in addition to our findings in chapter IV, suggest 
that n-3 PUFA, particularly DHA, might hold great therapeutic potential for CF 
patients. Many clinical trials, summarized in (Table 1)99-114, have investigated 
this potential by using n-3 PUFA administration in CF patients. While n-3 
PUFA administration in all of these studies showed significant reversal of 
characteristic PUFA alterations in tissues of CF patients, the clinical benefits of 
this administration were not as clear. This could be due to several issues in 
study design of these trials. First, most of these studies used a combination of 
EPA and DHA with varying concentrations, for short periods that most ranged 
from 2 weeks to 6-8 months, with the longest studies lasting 1 year. Second, 
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these trials were small, most having 20 patients or less. Finally, the use 
pulmonary function tests, such as FEV1, to gauge clinical improvement may 
not be the most reliable measure, since these tests change due to many 
factors, such as age and pulmonary exacerbations. Thus, future clinical trials 
must standardize the dose n-3 PUFA and duration of the study. Moreover, 
these future studies must identify a better clinical marker of the disease. 
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Table 1: Summary of n-3 supplementation clinical trials in CF  
 
Ref N and Age  Dose Duration Results 
195 9 CF patients 
(7-20 y) 
0.911 g/day n-3 
PUFA 
1 month Increased levels of 
DHA and EPA 
196 19 CF patients 
(12-20 y) 
2.7 g/day EPA 12 weeks Improved neutrophil 
chemotaxis in 
response to LTB4 
197 12 CF patients 
(12.2±5.4 y) 
3.2 g/day EPA 
2.2 g/day DHA  
6 weeks Increased DHA and 
EPA incorporation in 
RBCs 
198 14 CF patients 
(6-16 y) 
0.1 g/kg/day n-3 
PUFA 
2 weeks Increased levels of 
DHA and EPA 
Decreased LTB4 
levels in plasma 
199 9 CF patients 
(14-22 y) 
2.7 g/day EPA 6 weeks Corrected number 
and ligand affinity of 
LTB4 receptor 
200 23 CF patients 
(4-42 y) 
0.035 g/kg 
PUFA 
4 weeks Increased levels of 
EPA and DHA 
201 9 CF patients 
(12-29 y) 
0.150 g/kg IV n-
3 PUFA 
4 weeks Increased serum 
EPA and DHA 
No improvement in 
lung function 
202 5 CF patients 
(6-16 y) 
1.2-2.7 g/day 
EPA 
1.2-1.8 g/day 
1 year No significant 
change in number of 
hospital days 
203 30 CF patients 
(0.8-24 y) 
0.4 g/day EPA 
0.2 g/day DHA 
8 months Increased levels of 
DHA in and EPA 
Decreased AA  
Improved FEV1  
204 5 CF patients 
(18-43 y) 
0.070 g/kg DHA 6 weeks Increased levels of 
DHA 
Decreased levels of 
AA only in plasma 
PC and PE 
No improvement in 
lung function 
205 20 CF patients 
(8-20 y) 
0.050 g/kg DHA 6 months Increased DHA 
levels  
Decreased AA 
levels  
No improvement in 
lung function 
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180 17 CF patients 
(18±9 y) 
0.039-1.170 
g/day n-3 PUFA 
6 months Increased levels of 
EPA but not DHA  
No improvement in 
lung function 
206 9 CF patients 
12.1 y (IQR 9.3) 
3 g/day (40% 
DHA) 
1 year Increased levels of 
EPA and DHA 
Decreased levels of 
AA  
No improvement in 
lung function 
207 17 CF patients 
(26.4±10.6 y) 
0.324 g/day 
EPA 
0.216 g/day 
DHA 
1 year Increased levels of 
DHA but not EPA 
Decreased levels of 
AA 
Decreased levels of 
TNFα 
Improved FEV1 
Decreased number 
of exacerbations 
and number of 
antibiotic days 
208 41 CF patients 
(6-12 y) 
0.1 g/kg DHA, 1 
month 
1 g/day DHA, 11 
months 
1 year Decreased ratio of 
AA/DHA  
No improvement in 
lung function 
209 10 CF patients 
(6-18 y) 
0.1 g/kg/day 
DHA 1 
month 
0.25 g/kg/day 
DHA, 5 months 
6 months Decreased levels of 
IL-8, TNFα, and 
fecal calprotectin  
Improved absolute 
FEV1 only 
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Summary and Study Goal 
 The leading cause of mortality in CF is lung disease that is 
characterized by a self-perpetuating cycle of infection and inflammation. While 
the cause of the excessive inflammatory response in CF remains unclear, 
certain PUFA alterations that lead to increased production of AA, which is a 
precursor for a variety of oxygenated lipid mediators that can modulate 
inflammation, may provide a possible mechanistic explanation. Other PUFA 
abnormalities include a decrease in linoleic acid (LA) and docosahexaenoic 
acid (DHA). Studies have shown that these alterations in CF correlate with 
disease severity, and favor the increased metabolism of LA to AA. 
Furthermore, the literature demonstrates that there is an imbalance in the 
production of AA-derived inflammatory mediators. We hypothesize that 
inherent alterations in PUFA metabolism contribute to the inflammatory 
response and disease phenotype in CF via dysregulated eicosanoid 
production. This project will test the aforementioned hypothesis by examining 
the production of AA-derived eicosanoids and its relationship with PUFA 
metabolism. 
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CHAPTER II 
 
INTERACTIONS OF LINOLEIC AND ALPHA-LINOLENIC ACIDS IN THE 
DEVELOPMENT OF FATTY ACID ALTERATIONS IN CYSTIC FIBROSIS 
 
 
Introduction 
 Among the many phenotypic manifestations of this disease is 
pancreatic insufficiency, leading to malnutrition. As a result, CF patients 
require significant nutritional support to maintain body mass. Consensus 
recommendations suggest a high-calorie, high-fat diet 115. However, they are 
not specific as to the sources or types of dietary fat to be consumed. 
Consequently, there is increasing concern over the sources and types of fat in 
the typical CF diet 116. 
 CF patients exhibit alterations in tissue and plasma levels of 
polyunsaturated fatty acids (PUFA)117,118. These changes are independent of 
the effects of malabsorption, as they persist in patients receiving pancreatic 
enzyme replacement therapy, as is the standard of care 119. These results 
have been replicated in mouse120,121 and cultured cell 122 models of the 
disease. The major alterations seen are decreases in linoleic acid (LA; 18:2n-
6) and docosahexaenoic acid (DHA; 22:6n-3) and increases in palmitoleic acid 
(16:1n-7) and Mead acid (20:3n-9). Increased arachidonic (AA; 20:4n-6) is 
reported in some, but not all, studies. Multiple lines of evidence suggest a 
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connection between these abnormalities and CF pathophysiology. The 
magnitude of PUFA alterations correlate with disease severity 123-126, although 
it is unclear whether this represents cause or effect. However, correction of the 
abnormalities by dietary DHA supplementation, given as free fatty acids or 
glycerophospholipid liposomes, reversed CF-related pathology in mouse 
models 120,121. Some have theorized that elevated AA levels contribute to CF 
by increasing production of pro-inflammatory eicosanoids 118. 
 Recent work from our laboratory has demonstrated that the PUFA 
abnormalities observed in the CF cultured cell model are due to changes in 
fatty acid metabolism. The n-3 and n-6 PUFA are metabolized via parallel 
pathways that share common desaturase and elongase enzymes127. 
Compared with wild-type (WT) cells, CF cells exhibit increased expression and 
activity of fatty acid metabolic enzymes, including Δ5-, Δ6-, and Δ9-
desaturases, and elongase 6 causing increased production of AA, palmitoleic 
acid, and Mead acid 72,128. We further demonstrated that DHA and 
eicosapentaenoic acid (EPA; 20:5n-3) suppress the expression of both Δ5- 
and Δ6-desaturases and normalize LA and AA levels 129. These studies also 
showed some differences between the n-3 and n-6 metabolic pathways. 
Although they share the same enzymes, there was a clear preference for n-3 
substrates, especially in CF cells. 
 In the setting of increased AA production through the n-6 pathway, it is 
possible that variations in substrate (i.e., LA) concentrations play a significant 
role in the phenotypic manifestations of CF. Indeed, a recent study showed 
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that LA supplementation in cell culture and mouse CF models increased AA 
levels as well as the production of prostaglandin E2 (PGE2), PGF2α, and IL-8, 
leading to increased airway inflammation 130. This is of particular concern in 
CF patients consuming a high-fat diet, given that the typical Western diet is 
high in LA, but low in alpha-linolenic acid (LNA; 18:3n-3), its counterpart in the 
n-3 pathway 131. 
 In the current study we investigated the impact of varying 
concentrations of the initial fatty acids in the n-3 and n-6 pathways on the 
development of the classic fatty acid alterations in CF. Using a well-
characterized cell culture model of CF, we demonstrated that these alterations 
are strongly influenced by the input concentrations of both LA and LNA, and 
that LNA supplementation can markedly decrease production of AA, the fatty 
acid precursor of many pro-inflammatory eicosanoids. These results may have 
implications for nutritional management of patients with CF. 
 
Materials and Methods 
Materials: 
[1-14C]LA (55 mCi/mmol) and [1-14C]LNA (55 mCi/mmol) were 
purchased from American Radiolabeled Chemicals (St. Louis, MO). Fatty acid 
methyl ester (FAME) standards for HPLC were purchased from NuCheck Prep 
(Elysian, MN) or Larodan Fine Chemicals (Malmö, Sweden). HPLC grade 
solvents were purchased from Fisher Scientific (Pittsburgh, PA). Liquid 
scintillation cocktail (FlowLogic U) was purchased from LabLogic Systems, 
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Inc. (Brandon, FL). The different horse sera described in Table 1 were 
purchased from three different companies: “Serum 1” from Atlanta Biologicals 
(Lawrenceville, GA), lot #C1010; “Serum 2” from Invitrogen (Carlsbad, CA), lot 
#8131206; “Serum 3” from Omega Scientific (Tarzana, CA), lot #169101. 
 
Cell culture: 
Human bronchial epithelial cells (16HBEo−) expressing CFTR (WT) or 
not expressing CFTR (CF) were a kind gift from Dr. Pamela Davis (Case 
Western Reserve University School of Medicine, Cleveland, OH). 16HBE cells 
are immortalized human bronchial epithelial cells stably transfected with a 
segment of the CFTR gene in the sense or antisense orientation 132 that have 
been used widely to study PUFA alterations in CF 72,117,122,128,129,133. Cells with 
the sense gene (WT cells) have normal CFTR expression and activity, while 
those with the antisense gene (CF cells) lack both 122,132. Tissue culture flasks 
were coated with LHC basal media (Invitrogen) that contains 1 mg/mL BSA 
(Sigma-Aldrich, St. Louis, MO), 10 µg/mL human fibronectin (Sigma-Aldrich), 
and 3 µg/mL vitrogen (Angiotech Biomaterials, Palo Alto, CA). The cells were 
grown in MEM + glutamax (Invitrogen) with 10% horse serum, penicillin (100 
U/mL), and streptomycin (100 µg/mL) and maintained at 37oC in 5% CO2. The 
media was changed three times per week. 
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Fatty acid supplementation: 
 WT and CF cells were seeded at 3x105 and 1x105 cells/ well, 
respectively, onto 6-well plates and were grown for 7 days. On day 7, the cells 
were washed and fed medium containing 10% reduced-lipid FBS and 
supplemented with 0, 5,10, or 20 µM of LA or LNA for 4 hours. 
Supplementation media was prepared by adding media to free fatty acids (LA 
or LNA) that were dried under nitrogen in glass conical tubes followed by 
vortexing and sonicating three times for 5 seconds each to allow fatty acid 
binding to serum albumin.  
 
Fatty acid composition analysis: 
 Cells ready for analysis were washed twice with ice-cold PBS then 
harvested by scraping on ice with a rubber policeman and pelleted by 
centrifugation at 100xg for 8 min. The cell pellet was resuspended in 0.5 mL 
PBS and 10 µg of heptadecanoic acid (17:0) was added as an internal 
standard before extracting lipids according to the modified Folch method 134. 
Briefly, six volumes of chloroform-methanol (2:1 v/v) were added to the 
samples, after which they were incubated on ice for 10 min, vortexed, and 
centrifuged at 1100xg for 10 min. The resulting lower phase was transferred to 
a new tube and dried completely under nitrogen. Fatty acids were then 
methylated using boron trifluoride (BF3)-methanol and a methanolic-base 
reagent. After adding an aliquot of 0.5 mL 0.5 N methanolic NaOH to samples, 
they were vortexed and heated at 100oC for 3 minutes. This was followed by 
	  	  
	  
37	  
the addition of 0.5 mL BF3 and heating at 100oC for 1 minute. The resulting 
fatty acid methyl esters (FAMEs) were extracted using 1 mL hexane followed 
by 6.5 ml of saturated NaCl solution. FAMEs in the hexane layer were 
identified and quantified by gas chromatography (GC) using an Agilent 7980A 
GC system (Agilent Technologies, Santa Clara, CA) equipped with a 
Supelcowax SP-10 capillary column (Supelco, Bellefonte, PA) coupled to an 
Agilent 5975C mass spectrometer (MS). FAME mass was determined by 
comparing areas of unknown FAMEs to that of the 17:0 internal standard. 
Results were reported as the molar percentage (mol%) of each FAME relative 
to the total mass of the sample, as previously described 133.         
 
Fatty acid radiolabeling experiments: 
 On day 7, cells were incubated with media containing 10% horse serum 
(serum 3) supplemented with 0, 5, 10, or 20 µM of LA or LNA in addition to 4.1 
µM of either [1-14C]LNA or [1-14C]LA for 4 hours. Radiolabeled LNA was added 
to media supplemented with unlabeled LA, whereas radiolabeled LA was 
added to media supplemented with cold LNA. Lipids were extracted as 
described above. However, in these studies, the final hexane layer was dried 
under nitrogen and the FAMEs resuspended in 50 µL acetonitrile for HPLC 
analysis. FAMEs were separated by reverse-phase high performance liquid 
chromatography (RP-HPLC) using a binary solvent system on an Agilent 1200 
series instrument equipped with a (4.6 x 250 mm, 5 µm) Agilent zorbax 
Eclipse XDB-C18 column and a (4.6 x 12.5 mm, 5 µm) column guard. Solvent 
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A consisted of H2O + 0.02% H2PO4 and solvent B was 100% acetonitrile. The 
solvent program was 58% solvent B for 25 min, 58-61% B for 2 min, 61% B for 
8 min, 61-100% B for 15 min, 100% B for 20 min, and finally reconstitution to 
original conditions. Peaks were identified by UV detection at 205 nm and 
comparison with the retention times of unlabeled standards. Radiolabeled 
peaks were quantified using an IN/US β-RAM Model 4 scintillation detector 
coupled to the HPLC instrument. Results were reported as percentage of total 
measured counts in a sample.      
 
Statistical Analysis: 
 All results are representative of two or more identical experiments. 
Relative distributions of fatty acids under various conditions in CF and WT 
cells were compared using two-way analysis of variance (ANOVA). 
Comparison of CF and WT cells under each condition was performed using a 
Bonferroni post-test. Slopes of lines representing change in labeled EPA and 
AA versus concentration of added LA or LNA were calculated and compared 
using linear regression. All statistical analysis was performed using GraphPad 
Prism v5.0 software (GraphPad Software, La Jolla, CA). 
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Results 
 
Fatty Acid Composition of Different Horse Sera 
 Prior studies investigating PUFA abnormalities in CF cell culture models 
have used media containing horse serum because its relatively high content of 
LA accentuates n-6 PUFA abnormalities in this model135. However, over time 
we noted significant variation in these abnormalities when different lots of 
horse serum were used. To test whether these changes were due to 
differences in the fatty acid content of the sera, we cultured WT and CF cells 
in media containing three different horse sera, the fatty acid composition of 
which is shown in Table 1. The major fatty acids included the saturated fatty 
acids palmitic acid (16:0) and stearic acid (18:0), the monounsaturated fatty 
acid oleic acid (18:1n-9), and the PUFAs LA and LNA. Of these, there were 
significant lot-to-lot variations in LA, LNA, and oleic acid (Table 2). Other 
measured fatty acids individually represented <5% of the total fatty acid mass.  
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Table 2: 
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Relationship of Cellular LA and LNA to Serum LA and LNA Levels  
 To determine the impact of the different sera on PUFA metabolism in 
CF, we incubated WT and CF cells in media containing the different lots of 
horse serum for 7 days. We then measured the relative PUFA distributions of 
the cells (Fig. 7). There was no significant difference in relative LA levels 
between WT and CF cells incubated in medium containing serum 1 (Fig. 7a). 
However, WT cells incubated in sera 2 and 3 had higher LA levels than those 
of CF cells. To determine whether the serum concentrations of LA were 
responsible for these differences, the relative cellular LA levels were plotted 
against those of serum LA (Fig. 7c). There was a clear positive correlation 
between serum LA content and cellular LA composition. Furthermore, the 
characteristic difference in LA levels between WT and CF cells was apparent 
only with serum containing moderate to high (≥36%) LA levels (sera 2 and 3). 
 Significant differences in cellular AA levels were only noted in cells 
incubated in serum 3, with levels higher in CF than WT cells (Fig. 7b). Prior 
studies 128,130 indicated that AA levels should rise in proportion with increasing 
LA inputs and that this increase would be greater in CF versus WT cells. On 
the contrary, there was no apparent correlation between relative serum LA and 
cellular AA levels (Fig. 7d). Rather, AA levels were lowest in the cells grown in 
the serum with medium LA content (serum 2). Noting that serum 2 also 
contained the highest concentrations of LNA, we sought to determine whether 
serum LNA also influenced AA levels. Accordingly, we plotted cellular LA and 
AA levels against the serum LA:LNA ratio (Fig. 7e,f). While there was no 
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apparent relationship between LA:LNA and LA levels (Fig. 7e), there was a 
positive correlation between LA:LNA and AA levels, particularly in CF cells 
(Fig. 7). In fact, the AA increase characteristic of CF was apparent only at the 
highest LA:LNA ratio. These findings suggest that production of AA is 
influenced by LNA, the initial substrate of the parallel n-3 pathway, such that 
AA production is higher when LNA is low and vice versa. 
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Figure 7:  
Relationship of cellular LA and LNA concentrations to serum LA and 
LNA levels. Relative cellular LA (a,c,e) and AA (b,d,f) concentrations were 
measured by gas chromatography/mass spectroscopy (GC-MS) from extracts 
of WT and CF cells cultured for 7 days in media containing 10% horse serum 
from different lots (see Table 2 and Materials and Methods). Data are plotted 
as mean mole percent of each lipid (±S.E.M.; n=3) for cells treated with each 
of the three sera (a,b) or versus LA concentration (c,d) or LA:LNA ratio (e,f) in 
serum on the x-axes. WT cells are indicated by open circles (○) and CF cells 
by open squares in the line graphs (□). Statistical analysis performed using 
two-way ANOVA with pairwise comparisons calculated using Bonferroni post-
test (see Materials and Methods). ***, P<0.001; **, P<0.01. 
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Relationship of Cellular EPA and DHA Concentrations to Serum LA and LNA 
Levels 
 In light of the metabolic relationship between the n-3 and n-6 pathways, 
we sought to determine whether LA levels might also influence LNA 
metabolism in CF. Cellular EPA and DHA levels varied significantly between 
cells incubated with different sera (Fig. 8a,b). EPA levels were consistently 
higher and DHA level consistently lower in CF compared to WT cells as shown 
previously 128,129. Levels of cellular EPA and DHA, products of LNA 
metabolism, were plotted against serum LNA levels and serum LA:LNA ratios. 
In contrast with LA metabolism to AA in the n-6 pathway (Fig. 8), there was a 
strong positive relationship between serum LNA concentrations and cellular 
EPA and DHA levels in both WT and CF cells (Fig. 8,d), such that the low 
levels of DHA characteristic of CF were much more apparent in cells 
incubated in serum with higher concentrations of LNA. Accordingly, cellular 
EPA and DHA levels fell as the serum LA:LNA ratios increased (Fig. 8e,f).  
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Figure 8:  
Relationship of cellular EPA and DHA concentrations to serum LA and 
LNA levels. Relative cellular EPA (a,c,e) and DHA (b,d,f) concentrations were 
measured by gas chromatography/mass spectroscopy (GC-MS) from extracts 
of WT and CF cells cultured for 7 days in media containing 10% horse serum 
from different lots (see Table 2 and Materials and Methods). Data are plotted 
as mean mole percent of each lipid (±S.E.M.; n=3) for cells treated with each 
of the three sera (a,b) or versus LNA concentration (c,d) or LA:LNA ratio (e,f) 
in serum on the x-axes. WT cells are indicated by open circles (○) and CF 
cells by open squares in the line graphs (□). Statistical analysis performed 
using two-way ANOVA with pairwise comparisons calculated using Bonferroni 
post-test (see Materials and Methods). ***, P<0.001. 
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There are likely other differences besides fatty acid concentrations in 
the various sera that could potentially account for these changes. Thus, to 
confirm the impact of LNA on LA to AA metabolism, we incubated CF and WT 
cells in serum 3, which had the highest LA:LNA ratio, supplemented with LNA 
sufficient to reduce the ratio from 14 to 10 and 5 (Fig. 9). As serum LNA 
concentrations increased, relative cellular LA levels rose (Fig. 9a) and AA 
levels fell (Fig. 9b). AA:LA ratios, roughly indicative of desaturase activity, fell 
significantly with increasing LNA in both CF (2.01±0.03, 1.40±0.04, and 
0.72±0.01, respectively; P<0.001) and WT cells (1.29±0.02, 1.03±0.02, and 
0.53±0.01, respectively; P<0.001). 
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Figure 9: 
Effect of increasing concentrations of LNA on n-6 PUFA metabolism. WT 
and CF cells were cultured for 7 days as described in Materials and Methods 
in medium containing 10% serum 3 (see Table 2) with a LA:LNA ratio of 14.4:1 
supplemented with either no LNA, or additional LNA sufficient to lower the 
LA:LNA ratio to 10:1 or 5:1. Relative cellular LA (a) and AA (b) concentrations 
were measured by gas chromatography/mass spectroscopy (GC-MS) from cell 
extracts as described in Materials and Methods. Data are plotted as mean 
mole percent of each lipid (±S.E.M.; n=3). Statistical analysis performed using 
two-way ANOVA with pairwise comparisons calculated using Bonferroni post-
test (see Materials and Methods). ***, P<0.001. 
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Metabolism of n-3 and n-6 Precursors Is Suppressed by Addition of 
Exogenous Precursors from the Opposite Pathway 
To directly measured the effect of LNA on LA to AA metabolism, we 
incubated cells with radiolabeled LA in the presence of increasing 
concentrations of unlabeled LNA for four hours and then measure labeled LA 
and AA (Fig. 10a,b). As has been reported previously 128,133, there was greater 
conversion of LA to AA in CF versus WT cells, as indicated by lower levels of 
labeled LA and higher levels of labeled AA in CF cells. Addition of unlabeled 
LNA decreased metabolism of LA to AA, reflected in dose-dependent small 
increases in labeled LA and large decreases in labeled AA. These changes 
were greater in the CF cells, such that the differences in LA and AA levels 
between CF and WT cells completely disappeared as LNA levels were 
increased. 
 LA had a similar effect on labeled LNA metabolism (Fig. 10c,d). As has 
been noted previously97,136, conversion of LNA to EPA was significantly higher 
than the conversion of LA to AA, especially in CF cells, with labeled LNA-
derived EPA comprising nearly 50% of total counts (Fig. 10d), while labeled 
LA-derived AA represented less than 20% of total counts in CF cells (Fig. 
10b). Nevertheless, there was a dose dependent decrease in EPA production 
from LNA with increasing concentrations of unlabeled LA. As with LA 
metabolism, this effect was larger in CF than in WT cells. In this case, the 
differences between the CF and WT cells persisted even at the highest 
concentrations of LA. 
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 To compare the effects of LA on LNA metabolism with those of LNA on 
LA metabolism, we compared slopes of calculated linear regression lines for 
the data in Figures 10b and 10d. The calculated rates of decline were similar 
between LA and LNA for both CF (0.71±0.17% AA/µM LNA versus 
1.00±0.05% EPA/µM LA; P=0.17) and WT cells (0.39±0.17% AA/µM LNA 
versus 0.31±0.04% EPA/µM LA; P=0.67). 
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Figure 10:  
Metabolism of n-3 and n-6 precursors is suppressed by addition of 
exogenous precursors from the opposite pathway. WT (○) and CF (□) 
cells were cultured for 7 days in medium containing 10% serum 3 as described 
in Materials and Methods. On day 7, the medium was replaced with reduced-
lipid medium containing 4.1 µM [1-14C]LA (a,b) or [1-14C]LNA (c,d) and 0, 5, 
10, or 20 µM unlabeled LNA (a,b) or LA (c,d). After labeling for 4 hours, cells 
were washed and refed complete medium. After culturing for an additional 20 
hours, cells were harvested and levels of labeled LA (a), AA, (b), LNA (c), and 
EPA (d) were determined by HPLC and scintillation counting as described in 
Materials and Methods. Data are expressed as percent of total counts and 
points represent the mean ± S.E.M (n=3). Statistical analysis performed using 
two-way ANOVA with pairwise comparisons calculated using Bonferroni post-
test (see Materials and Methods). ***, P<0.001. 
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Discussion 
 
 These results highlight the interaction between substrates of the n-3 
and n-6 PUFA metabolic pathways, demonstrating that the principal initial 
substrate of one pathway can suppress metabolism in the other pathway. The 
most obvious explanation for this effect is substrate competition for the 
common metabolic enzymes. However, effects on the expression of these 
enzymes cannot be ruled out as a cause. In fact, our group has previously 
demonstrated that LNA can reduce Δ5- and Δ6-desaturase expression 129. It is 
likely that the observed changes are due to a combination of these and other 
effects. 
 Another possible explanation for the reduction of AA production by LNA 
is that increased abundance of one fatty acid reduces the relative abundance 
of others by dilution. While this may be true to some extent, it cannot account 
for all of the results. For example, if dilution accounted for the reduction of AA 
concentrations with addition of LNA (Fig. 9), one would expect that LA levels 
would also be reduced by dilution. In fact, the opposite is true. In addition, 
dilution effects cannot account for the results of Figure 13, as the data is 
presented as a percentage of total counts from labelled fatty acids, while the 
potential diluent is unlabelled. 
 Several results suggest differences in these effects between CF and 
WT cells. In Figure 10f, AA production in CF cells appears to be more 
responsive to the LA:LNA ratio than WT cells, such the AA level are 
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significantly higher in CF cells at the highest ratio. Similarly, LA to AA 
metabolism appears to be more sensitive to LNA levels in CF than WT cells, 
such that the difference AA production (higher in CF cells) at baseline declines 
and then disappears as LNA levels rise. 
The observations are consistent with the clear differences in PUFA 
metabolism that have been described in CF cells 128,129,133. However, 
differences in oxidation and uptake could also play a role in the metabolic 
differences of fatty acids between CF and WT cells. Further studies are 
required to enumerate the relative contribution of this various pathways. 
In the experiments detailed in Figures 7 and 8, it appears that the serum ratio 
of LA to LNA has a greater impact on LA to AA metabolism than on LNA to 
EPA metabolism. Prior studies have demonstrated that the common metabolic 
pathway favors LNA to EPA metabolism over that of LA to AA 137-139, a result 
that has been confirmed by our group 128,129. Thus, LNA may compete more 
effectively for the common metabolic enzymes than LA. A second 
consideration is that the cellular concentration of LA is at least an order of 
magnitude higher than that of LNA in these cells (data not shown). Thus, 
exogenous addition of LNA has a greater fractional impact on the cellular LNA 
concentration than exogenous LA has on cellular LA concentrations, which 
may also account for some differences. It is important to note, however, that 
there was no statistical difference between the impact of LNA on labeled LA 
metabolism and the effect of LA on labeled LNA metabolism in the 
experiments detailed in Figure 10. 
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 These findings have implications for the experimental conditions used 
to study CF metabolism in animal and cell culture models. Our group has 
previously shown that the PUFA abnormalities characteristic of CF are 
observed in cell culture models when the cells are incubated in horse serum 
with higher concentrations of LA, but not in fetal bovine serum that has low 
concentrations of LA 122. Looking at LA levels alone, the current study seems 
to indicate that at least 36% serum LA is required to show differences in 
cellular LA concentrations between WT and CF cells, and higher levels are 
required to observe differences in AA. However, LA levels in plasma of CF 
patients with typical tissue PUFA abnormalities only range between 19-26% 
140. But as these results show, differences in AA are dependent on both LA 
and LNA input concentrations, with higher LA and lower LNA favoring the 
appearance of increased AA production. In this light, it is important to note that 
typical plasma LA:LNA ratios are greater than 100:1 141. In addition, these 
technical issues may explain why occasional studies have failed to detect the 
characteristic PUFA abnormalities in CF models71,72. It should be noted that 
LA and LNA were not the only PUFAs whose levels differed between the 
tested sera (Table 2). However, they were the most abundant of these fatty 
acids in the sera by far, and thus, expected to have the greatest impact on 
metabolism. 
 These results may have important implications for nutritional therapy of 
CF. Nutritional recommendations for CF patients include a high-calorie, high-
fat diet to counteract the effects of malabsorption 115. However, there are no 
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recommendations regarding the particular fatty acid content. The modern 
western diet has an LA:LNA ratio that is significantly higher than historic 
norms, and this ratio has increased substantially over the past century 142,143. 
The data presented here suggest that these higher ratios may accentuate the 
metabolic abnormalities that are thought to contribute to the pathophysiology 
of CF. Of particular concern is increased production of AA, which is thought to 
play a role in CF-related inflammation 118. Indeed, Zaman et al. have 
demonstrated that increased LA consumption increased AA production in both 
CF cells and CFTR knockout mice, leading to increases in inflammatory 
mediators and enhanced airway inflammation 130. These data suggest that 
attention should be paid to the sources of fat in the CF diet. However, the 
current report is restricted to a cell culture model lacking CFTR expression and 
further study is needed to assess the impact of these dietary factors in clinical 
outcomes of patients with more typical CFTR mutations. 
 Of particular interest is the role that LNA might be playing in the 
metabolism of n-6 fatty acids. Dietary LNA has significant beneficial health 
effects, particularly in the prevention of cardiovascular disease that may be 
due, in part, to its anti-inflammatory effects144,145. While this may be due to 
conversion of LNA to the known anti-inflammatory metabolites of DHA, the 
conversion from LNA to DHA is extremely limited 146. The data described here 
support older data that LNA may exert its beneficial effect by reducing 
metabolism of LA to the more pro-inflammatory AA 147 and that this is due to a 
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greater affinity for LNA than LA by desaturase enzymes 148,149. Therefore, this 
may be more relevant than its role as a substrate for DHA production. 
 In summary, we demonstrate the role that LA and LNA play in the 
development of PUFA abnormalities characteristic of CF both as precursors in 
their own metabolic pathways and as modulators of the parallel pathways in 
PUFA metabolism. Delineating these relationships may have important 
implications for understanding CF pathophysiology as well as nutritional 
therapy of this disease. 
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CHAPTER III 
 
INCREASED UPTAKE AND RELEASE OF ARACHIDONIC ACID IN 
CULTURED BRONCHIAL EPITHELIAL CELLS WITH A CYSTIC FIBROSIS 
PHENOTYPE 
 
 As shown in chapter II, there is an increased production of AA in CF 
cells when its substrate LA is readily available. However, the cause behind the 
increased AA production was not delineated. Here we will demonstrate that 
this may be due to an increased demand in CF cells for this biologically active 
fatty acid.   
 
Introduction 
  The increased inflammation in CF has been shown to involve a variety 
of mediators that include cytokines and oxygenated products of fatty acids 
85,94. Eicosanoids are oxygenated products derived from 20-carbon fatty acids, 
especially AA, and play an important role in inflammation in CF. The release of 
AA from membrane phospholipids is an important rate-limiting step in the 
production of AA-derived pro-inflammatory eicosanoids, and AA release is 
reported to be increased in CF. Carlstedt-Duke et al. 81 and Strandvik et al. 150 
reported that defective regulation of AA release is an important defect in the 
pathology of CF. Miele et al. showed that AA release is increased in human 
pancreatic epithelial cells that express mutated CFTR in response to A23187 
82. 
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In this study we utilized a human bronchial epithelial cell line 
(16HBEo−) sense or wild type (S or WT) and antisense (AS, CF) to study the 
uptake of radiolabeled AA by cells. We also characterized the calcium-
dependent release of AA in these cells in response to calcium ionophore 
A23187 and by late phase filtrate from Pseudomonas aeruginosa that is 
commonly found in infected CF lungs. CF cells exhibited both higher AA 
uptake and higher AA release, in association with increased expression of 
cytosolic phospholipase A2 (cPLA2α). Stimulation with late phase 
Pseudomonas aeruginosa filtrate caused a significant amplification of this 
response.   
 
Materials and Methods 
Materials: 
[1-3H]AA (200 Ci/mmol) was purchased from American Radiolabeled 
Chemicals (St. Louis, MO). HPLC standards for arachidonic acid, PGE2, PGD2 
and PGF2α were purchased from NuCheck Prep (Elysian, MN) or Cayman 
Chemicals (Ann Arbor, MI). HPLC grade solvents were purchased from Fisher 
Scientific (Pittsburgh, PA). Liquid scintillation cocktail (FlowLogic U) was 
purchased from LabLogic Systems, Inc. (Brandon, FL). Liquid scintillation 
cocktail (BioSafe II) was purchased from (RPI, Mount Prospect, IL). 
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Cell Culture: 
Human bronchial epithelial cells (16HBEo−) expressing CFTR (S, 
sense; WT) or not expressing CFTR (AS, antisense; CF) were a kind gift from 
Dr. Pamela Davis (Case Western Reserve University School of Medicine, 
Cleveland, OH). Cells with the sense gene (WT cells) have normal CFTR 
expression and activity, while those with the antisense gene (CF cells) lack 
both 122,132 The cells were grown in MEM + glutamax (Invitrogen) with 10% 
horse serum, penicillin (100 U/mL), and streptomycin (100 µg/mL) and 
maintained at 37oC in 5% CO2. Cells were seeded in 6-well plates and grown 
for 7 days and the medium was changed every 2 days. 
 
Quantitative Real-Time PCR: 
Total RNA was isolated from cells using TRIzol (Life Technologies, 
Carlsbad, CA) and contaminating DNA was removed from samples by DNA-
free (Ambion, Austin, TX). cDNA was synthesized from 1 µg of total RNA 
using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Quantitative real-
time PCR was performed in 10 µL reactions containing 50 ng cDNA, TaqMan 
primer-probes sets and TaqMan Universal PCR Master Mix in 96-well plates 
(Life Technologies, Carlsbad, CA). Each reaction was performed in triplicate. 
Ct values were determined using the CFX96 Real Time PCR Detection 
System with CFX Manager software (Bio-Rad, Hercules, CA). Relative mRNA 
levels were calculated using the comparative Ct method while RPLP0 was 
used as a reference gene. 
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siRNA Knockdown: 
Cytoplasmic phospholipase A2 (cPLA2α) siRNA or negative control 
were purchased from Life Technologies (Carlsbad, CA). Cells were seeded 
and allowed to attach overnight. After 24 hours, 40-60% confluent cells were 
transfected using Lipofectamine RNAiMax (Invitrogen) according to the 
manufacturer’s instructions, using 50 nmol of total siRNA. Transfections were 
repeated on days 4 and 6. On day 7, RNA was harvested and analyzed by 
qRT-PCR to determine the efficiency of the knockdown.   
Pseudomonas aeruginosa Filtrate (PaF) Stimulation 
Late phase filtrate (PaF) was prepared from a stable mucoid Pseudomonas 
aeruginosa isolate from the lungs of a cystic fibrosis patient as described 
previously 151. Briefly, Pseudomonas was grown in 4% peptone (BD 
Diagnostics) at 37oC for 72 hours with shaking at 270 RPM. The filtrate was 
then collected and centrifuged at 10,000 RPM for 1 hour at 4oC followed by 
filtration through a 0.22 µm filter (Nalgene). The filtrate was heat inactivated at 
95oC for 10 minutes prior to use.  
 
Arachidonic Acid Uptake: 
On day 7, cells were washed twice with PBS + (5 mg/ml) BSA, then 
incubated with medium containing 10% reduced lipid FCS and supplemented 
with 0.5 nM [1-3H]AA for 5, 15, 30, or 60 minutes. After the incubation, the 
medium was aspirated and two 500 µL aliquots were counted in a Beckman 
Coulter LS 6500 Multi-Purpose Scintillation Counter (LSC) as a control. 
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Subsequently, the cells were washed three times with PBS + (5 mg/ml) BSA, 
then lysed with 1N NaOH and two 500 µL aliquots were counted by LSC to 
quantitate AA uptake. 
 
Arachidonic Acid Release: 
On day 7, cells were washed twice with PBS + (5 mg/ml) BSA, then 
incubated for 24 hours with medium that contained 10% reduced lipid FCS 
and supplemented with 0.5 nM [1-3H]AA. After the incubation, the medium was 
aspirated and two 500 µL aliquots were counted by LSC. Subsequently, the 
cells were washed three times with PBS + (5 mg/ml) BSA, then incubated for 
5, 10, 15, or 30 minutes with medium that contained 2 mg/ml BSA and varying 
concentrations of A23187 in the presence or absence of PaF or cPLA2α 
siRNA. After the stimulation, the medium was aspirated and cells were 
washed three times with PBS + (5 mg/ml) BSA, then lysed with 1N NaOH and 
two 500 µL aliquots of both release medium and lysates were counted by 
LSC. The percent AA release was calculated from dpm counts as [Release 
Medium / (Release Medium + Cell Lysate)] x 100.  
 
HPLC Analysis: 
The Release medium was extracted and analyzed by reverse phase 
high performance liquid chromatography (RP-HPLC) followed by quantitation 
of radioactivity in a liquid scintillation detector. Release medium collected after 
A23187 stimulation for 15 minutes, as described above, was acidified to pH 3 
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using 1 N HCl. The samples were then extracted using 100 mg C18 Restek 
SPE Cartridges (Bellefonte, PA). Eicosanoids were eluted from the SPE 
cartridges with ethyl acetate followed by methanol. Eluted samples were dried 
under nitrogen and then reconstituted in 50 µL solvent A for HPLC analysis. 
RP-HPLC separation was performed on a 1200 series Agilent HPLC system 
equipped with a (4.6 x 250 mm, 5 µm) Agilent Zorbax Eclipse XDB-C18 
column and a (4.6 x 12.5 mm, 5 µm) column guard. The separation system 
was set as 15 minutes of 100% solvent A acetonitrile/H2O/acetic acid 
(38:62:0.01 by vol), followed by 15 minutes of 100% solvent B 
acetonitrile/H2O/acetic acid (70:30:0.01 by vol), and finally 15 minutes of 100% 
acetonitrile. Radiolabeled peaks were identified by comparing their retention 
times to the retention times of unlabeled standards identified by UV detection 
at 205. Quantification of the radioactivity in individual peaks was with an IN/US 
β-RAM Model 4 scintillation detector coupled to the HPLC instrument.  
 
Statistical Analysis: 
Data comparison was performed using t test or two-way ANOVA with 
Bonferroni post-test for pairwise comparisons as described in Figure Legends 
using Prism 6 (GraphPad Software, La Jolla, CA). P<0.05 was considered 
statistically significant. 
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Results 
 
Arachidonic Acid Uptake Is Increased in CF Cells 
Previous work from our group showed that there is increased 
metabolism from LA to AA in CF cells 71. Due to the importance of AA as a 
precursor for pro-inflammatory eicosanoids, we were interested in 
investigating whether there is an increased demand for AA in CF cells. To that 
end, we examined the uptake of AA by WT and CF cells by incubating 
confluent cells with 0.5 nM [1-3H]AA for several time points. After radiolabeled 
AA incubation, the medium was removed and radioactivity quantified by LSC. 
CF cells showed increased uptake of [1-3H]AA at 15, 30, and 60 minutes 
(Figure 11). This indicates that CF cells have higher demand for AA, which 
may be due to increased utilization of this fatty acid by those cells.  
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Figure 11:  
Uptake of [1-3H]AA is increased in CF cells. 16HBEo− (S, WT) and (AS, 
CF) cells were grown for 7 days. On day 7, cells were incubated with 0.5 nM 
[1-3H]AA for 5, 15, 30, or 60 minutes. After the incubation, cells were lysed 
with 1N NaOH, and two 500 µL aliquots of the cell lysate were counted by 
LSC to measure uptake as described in Materials and Methods. Bars 
represent mean ± SEM (n=3). These results represent one of two independent 
experiments. Unlike letters indicate significant pairwise comparison differences 
with P at least <0.05. 
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Calcium-dependent Arachidonic Acid Release Is Increased in CF Cells 
In our next set of experiments, we examined the relative amount of AA 
release in both WT and CF cells. The incorporation of radiolabeled AA was 
similar between WT and CF cells after 24 hours of incubation (Figure 12a). For 
this reason, the cells were incubated with radiolabeled for 24 hours in AA 
release studies. After a 24-hour incubation with 0.5 nM [1-3H]AA, confluent 
cells were stimulated for 15 minutes with 1 µM calcium ionophore A23187. 
After stimulation, the medium was removed and radioactivity was measured by 
LSC. We saw that increasing cytosolic Ca2+ concentrations by stimulating the 
cells with A23187 for 15 minutes caused a significantly greater increase in AA 
release from CF cells than WT cells (Figure 12b). To make certain that the 
measured radioactivity was mainly [1-3H]AA, we extracted and analyzed the 
release medium by RP-HPLC connected to a LSC. The main radiolabeled 
peak that we detected corresponded to the peak of free AA (Figure 12c). 
Additionally, AA release was significantly higher in CF cells after 15 or 30 
minutes stimulation with 1 µM of A23187 (Figure 13a). Increasing A23187 
concentration from 2.5 to 10 µM amplified AA release from both cell lines, but 
release was always higher in CF cells (Figure 13b). 
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Figure 12: 
A23187-induced AA release is increased in CF cells. 16HBEo− (S, WT) 
and (AS, CF) cells were grown for 7 days. (A) On day 7, cells were incubated 
with 0.5 nM [1-3H]AA for 8 or 24 hours. After the incubation, cells were lysed 
with 1N NaOH, and two 500 µL aliquots of the cell lysate were counted by 
LSC to measure uptake as described in Materials and Methods. Alternatively, 
cells were incubated with 0.5 nM [1-3H]AA overnight. After 24 hours, cells 
were incubated for 15 minutes with either 1 µM of A23187 or DMSO. After the 
stimulation, the medium was collected (Release Medium) (B) Cells were lysed 
with 1N NaOH, and two 500 µL aliquots of both Release Medium and cell 
lysate were counted by LSC. The percent AA release was calculated from 
dpm as [Release Medium / (Release Medium + Cell Lysate)] x 100 as 
described in Materials and Methods; (C) (Release medium) was extracted for 
eicosanoid measurement, then analyzed by RP-HPLC connected to a liquid 
scintillation counter as described in Materials and Methods. Bars represent 
mean ± SEM (n=3). These results represent one of two independent 
experiments. Unlike letters indicate significant pairwise comparison differences 
with P at least <0.05. 
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Figure 13:  
Increase in calcium-induced AA release in CF cells. 16HBEo− (S, WT) and 
(AS, CF) cells were grown for 7 days. On day 7, cells were incubated with 0.5 
nM [1-3H]AA overnight. After 24 hours, cells were incubated (A) with 1 µM of 
A23187 for 5, 10, 15, or 30 minutes; or (B) for 15 minutes with 1 µM, 2.5 µM, 
10 µM of A23187 or DMSO. After the stimulation, medium was collected 
(Release Medium), cells were lysed with 1N NaOH, and two 500 µL aliquots of 
both Release Medium and cell lysate were counted by LSC. The percent AA 
release was calculated from dpm as [Release Medium / (Release Medium + 
Cell Lysate)] x 100, as described in Materials and Methods. Open circles (○, 
CF) and open squares (□, WT) represent mean ± SEM (n=3). These results 
represent one of two independent experiments. ***P<0.001, *P<0.05. 
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Cytosolic Phospholipase A2 (cPLA2α) Plays an Important Role in the 
Increased Calcium-induced Arachidonic Acid Release in CF Cells 
Cytosolic phospholipase A2 is a calcium-dependent enzyme that frees 
AA from the sn-2 position in membrane phospholipids. It is thought that the 
free AA released by this enzyme is mostly destined for eicosanoid production. 
Therefore, elucidating its role in CF may shed light on the role of AA in the 
inflammatory response in this disease. We first compared mRNA expression 
levels of both cPLA2α and cPLA2β between confluent WT and CF cells. We 
found that the mRNA expression of both enzymes was higher in CF cells 
(Figure 14a). To determine the contribution of cPLA2α in the increased Ca2+-
induced AA release in CF cells we performed siRNA knockdown of the gene in 
both cell lines. The knockdown caused 80% and 86% decrease in mRNA 
expression of cPLA2α in WT and CF cells, respectively (Figure 14b). 
Importantly, the knockdown in CF cells was accompanied by a 36% decrease 
in AA release in response to stimulation for 15 minutes with 2.5 µM of A23187, 
while it remained the same in WT cells (Figure 14c).   
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Figure 14: 
Cytosolic Phospholipase A2 contributes to AA release. 16HBEo− (S, WT) 
and (AS, CF) cells were grown for 7 days. (A) On day 7, mRNA was extracted, 
cDNA was synthesized, and primers for the mRNA sequences for cytosolic 
phospholipase A2α (cPLA2α) and cPLA2β were used for qRT-PCR analysis as 
described in Materials and Methods. (B) cPLA2α siRNA knockdown 
decreased the calcium-induced AA release in CF cells. 16HBEo− (S, WT) and 
(AS, CF) cells were transfected using Lipofectamine RNAiMax (Invitrogen) 
according to the manufacturer’s instructions and grown for 7 days. On day 7, 
mRNA was extracted, cDNA was synthesized, and primers for the mRNA 
sequences for cytosolic phospholipase A2α (cPLA2α) was used for qRT-PCR 
analysis as described in Materials and Methods. Alternatively (C), cells were 
incubated with 0.5 nM [1-3H]AA overnight. After 24 hours, cells were incubated 
for 15 minutes with either 2.5 µM of A23187 or DMSO. After the stimulation, 
medium was collected (Release Medium), cells were lysed with 1N NaOH, and 
two 500 µL aliquots of both Release Medium and cell lysate were counted by 
LSC. The percent AA release was calculated from dpm as [Release Medium / 
(Release Medium + Cell Lysate)] x 100 as described in Materials and 
Methods. Bars represent mean ± SEM (n=3). These results represent one of 
two independent experiments. ***P<0.001, **P<0.01. Unlike letters indicate 
significant pairwise comparison differences with P at least <0.05. 
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Inflammatory Stimulation with Pseudomonas aeruginosa Late Phase Filtrate 
Amplifies the Calcium-induced Arachidonic Acid Release in CF Cells 
Assessing whether AA release is influenced by inflammatory stimulation 
may be important in identifying the role of AA in the increased inflammatory 
response in CF. To that end, we used late phase Pseudomonas aeruginosa 
filtrate (PaF) as an inflammatory stimulus in addition to A23187, and measured 
AA release from confluent WT and CF cells by LSC. We found that AA release 
was higher in CF cells after stimulation for 15 minutes with 2.5 µM of A23187. 
AA release was amplified significantly when the cells were stimulated by both 
A23187 and PaF for 15 minutes and was higher in CF cells relative to WT 
cells (Figure 15). These findings suggest that AA release may be contributory 
to the excessive inflammatory response in CF by increasing the availability of 
AA as a substrate for the production of pro-inflammatory eicosanoids.   
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Figure 16: 
Stimulation with late-phase Pseudomonas filtrate (PaF) enhances the 
calcium-induced AA release in CF cells. 16HBEo− (S, WT) and (AS, CF) 
cells were grown for 7 days. On day 7, cells were incubated with 0.5 nM [1-
3H]AA overnight. After 24 hours, cells were incubated for 15 minutes with 2.5 
µM A23187, PaF + 2.5 µM A23187 or DMSO. After the stimulation, medium 
was collected (Release Medium), cells were lysed with 1N NaOH, and two 500 
µL aliquots of both Release Medium and cell lysate were counted by LSC. The 
percent AA release was calculated from dpm counts as [Release Medium / 
(Release Medium + Cell Lysate)] x 100 as described in Materials and 
Methods. Bars represent mean ± SEM (n=3). These results represent one of 
two independent experiments. Unlike letters indicate significant pairwise 
comparison differences with P at least <0.05. 
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Discussion 
 
In this study, we showed that there is an increased uptake of AA and 
AA release in CF cells compared to their WT counterparts. Moreover, we 
demonstrated that cytosolic phospholipase A2 plays an important role in AA 
release. It was also shown that stimulation by late phase Pseudomonas 
aeruginosa filtrate was able to amplify the calcium-induced AA release in CF 
cells. These results provide a link from the observed increase in LA to AA 
metabolism and lung inflammation in CF. These findings also suggest new 
approaches for dietary management in CF.  
The observed increased uptake of AA after 15 minutes and up to 60 
minutes in CF cells compared to WT cells in this study is in agreement with a 
previous report that showed there was 30% increase in AA uptake by CF cells 
after 10 minute pulse experiments 82. The increased uptake of AA by CF cells 
may indicate higher demand for this fatty acid. This could be related to the 
apparently increased consumption of AA for the production of pro-
inflammatory eicosanoids.  
Levistre et al. investigated the release of AA in tracheal epithelial cells 
in response to bradykinin and found that CF cells exhibited higher AA release 
that is related to cPLA2 152. Similarly, in human bronchial epithelial cells 
(16HBEo−), we found that AA release was higher in CF cells than in WT cells 
in response to calcium ionophore A23187. We demonstrated that AA release 
	  	  
	  
73	  
was apparently dependent on intracellular Ca2+ concentrations as AA release 
increased with longer exposure times as well as higher doses of A23187.  
A study by Wu et al. showed that cytosolic phospholipase A2 (cPLA2α) 
inhibition or knockout in CF mice was able to reduce LPS-induced airway 
constriction 153. Another study by the same group reported that the activity of 
cPLA2α was associated with mucus overproduction in the lungs of CF mice in 
response to LPS stimulation 154. In our study, we saw that the expression of 
both calcium dependent cytosolic phospholipases cPLA2α and cPLA2β was 
higher in CF compared to WT cells. This appeared to play a role in the 
elevated AA release observed in CF cells since siRNA knockdown of cPLA2α 
caused a significant decrease in the A23187-dependent AA release. The 
knockdown did not lower AA release in CF cells to WT levels. One possible 
explanation is that the mRNA expression in CF cells for cPLA2α remained 5-
fold higher compared to WT cells after the knockdown. Another possible 
explanation is there is a contribution of cPLA2β, which is also elevated in CF 
cells, in the release of AA. We also measured the mRNA expression of 
calcium-dependent secretory phospholipase A2 (sPLA2-IIA) and found that 
there was no difference in expression between WT and CF cells (data not 
shown). This does not rule out the involvement of sPLA2-IIA completely as 
activity of this enzyme may account for a portion of the increased AA release 
in CF cells.  
Arachidonic acid release from membrane phospholipids is an important 
rate-limiting step in the production of AA-derived pro-inflammatory 
	  	  
	  
74	  
eicosanoids. The cyclooxygenase-2 (COX-2) and 5-lipoxygensae (5-LOX) 
pathways are two of the main pathways in inflammation-related eicosanoid 
production. While all products of the COX-2 and 5-LOX pathways play an 
essential role, prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) are 
especially important in the inflammatory response. LTB4 is a potent neutrophil 
chemoattractant, while PGE2 affects many cellular processes via cAMP and/or 
Ca2+ signaling 43. Pseudomonas aeruginosa (Pa) is responsible for the 
majority of lung infections in CF patients at an early age, and their infections 
lead to tissue destruction and subsequently to mortality. The above mentioned 
AA-derived eicosanoids are thought to be important participants in the CF 
inflammatory response that leads to neutrophil accumulation and the ensuing 
tissue destruction 155, as many COX-2 and 5-LOX products have been shown 
to be increased in patients and various models of CF 71,83-87,89,90. Therefore, 
the study of AA release in response to Pa inflammatory stimulation is 
important in understanding the contribution of AA and its metabolites in the 
pathology of CF. To study this, we used late phase Pseudomonas aeruginosa 
filtrate (PaF) in addition to A23187 to assess the role of inflammatory 
stimulation in calcium-induced AA release. PaF stimulation caused a 
significant increase in the AA release in CF cells compared to WT cells. This 
adds further evidence that the increased AA release may contribute to the 
inflammatory response in CF by increasing the availability of AA for the 
production of AA-derived eicosanoids.  
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The results in this report demonstrate a possible link between the 
observed PUFA alterations and the inflammatory response in CF. Previous 
work from our group showed that LA levels were lower, while AA levels were 
higher, in CF compared to WT cells. This was accompanied by an increase in 
the expression and activity of Δ6- and Δ5- desaturase that led to increased 
metabolism of LA to AA in the n-6 pathway 71. CF cells may require higher 
amounts of AA to produce larger amounts of pro-inflammatory eicosanoids, 
which may lead to the observed increased metabolism from LA to AA and 
elevated uptake of AA. Other published work by our group has shown that n-3 
fatty acids, namely (LNA, 18:3n-3) and (DHA, 22:6n-3), are able to decrease 
the levels of AA in CF cells by direct competition for or inhibition of the 
metabolic enzymes shared by the n-3 and n-6 pathways 97,156. These findings 
suggest the need for a change in the dietary recommendation for CF patients, 
in which n-6 fatty acid intake is decreased and n-3 fatty acids is increased, in 
order to decrease the levels of AA.  
 In summary, the data reported in this study demonstrate that there is 
dysregulation in AA utilization in CF bronchial epithelial cells compared with 
WT controls that leads to increased uptake and release of this fatty acid. The 
dysregulation of AA uptake and release may be highly contributory to the 
inflammatory response in CF. 
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CHAPTER IV 
 
PRODUCTS OF THE 5-LIPOXYGENASE PATHWAY MEDIATE 
CYCLOOXYGENASE-2 AND CYTOKINE OVEREXPRESSION IN 
RESPONSE TO PSEUDOMONAS AERUGINOSA IN AN AIRWAY 
EPITHELIAL CELL MODEL OF CYSTIC FIBROSIS 
 
The work presented in chapter III establishes that CF cells uptake more 
AA and release more of this fatty acid in response to stimulation. Here we will 
show that this dysregulation in AA utilization leads to the elevated 
inflammatory response through products of the 5-LOX pathway.   
 
Introduction 
Mutations in the CFTR gene cause varying degrees of channel 
dysfunction, affecting multiple tissues. However, most morbidity and mortality 
in CF are due to progressive pulmonary failure 7. In the lungs, defective 
channel function compromises mucociliary clearance, causing obstruction of 
respiratory passages by thick, viscid mucus 11. This establishes a vicious cycle 
of obstruction, infection, and inflammation, which leads to tissue destruction 
157. In particular, enhanced inflammation appears to play a significant role in 
CF pathophysiology. Infected CF airways exhibit marked inflammation, 
characterized by profuse neutrophil infiltration and production of pro-
inflammatory cytokines, such as interleukin (IL)-1β, IL-6, and IL-8 158. This 
inflammation appears to be disproportionate to levels of infection 26. In fact, 
there is evidence to suggest that inflammation may be increased even in the 
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absence of infection 159-161. These findings imply that CFTR mutations may 
establish a uniquely pro-inflammatory state, although the mechanisms are 
poorly understood. 
Eicosanoids are among the mediators that could be responsible for 
enhanced inflammation in CF. There is considerable evidence for abnormal 
eicosanoid biosynthesis in CF. Production of prostaglandins and leukotrienes 
is increased in CF patients 94,162-168, while lipoxin production appears to be 
reduced 169,170. These changes are associated with increased expression of 
COX-2 and 5-LOX in CF patient tissues 91,171 and in epithelial cell culture 
models of CF 128. 
As a major source for the production of pro-inflammatory eicosanoids, 
AA availability is a limiting factor for the production of these mediators. 
However, a number of studies have demonstrated increased metabolism of 
AA from its precursor fatty acid, linoleic acid (LA; 18:2n-6) in CF cells 120-
122,133,172. This is due to increased expression of Δ5- (Δ5D) and Δ6-
desaturases (Δ6D) in CF cells 128,129 and accounts for the plasma PUFA 
alterations consistently observed in CF patients [reviewed in 117,118]. Dietary 
studies in animal models suggest that this altered PUFA metabolism may have 
an impact on inflammation. Lungs of CFTR-/- knockout mice supplemented 
with LA show increased AA levels and markedly increased neutrophil 
production in response to an inflammatory stimulus 130. On the other hand, 
CFTR-/- knockout mice supplemented with docosahexaenoic acid (DHA; 
22:6n-3), which is known to suppress expression of the fatty acid desaturases 
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129, exhibit reduced AA levels and decreased neutrophil production in the 
lungs 120. 
While these studies are suggestive, the relationships between 
abnormalities in PUFA metabolism, eicosanoid production, and inflammation 
in CF are incompletely understood. In this report, we test the hypothesis that 
alterations in PUFA and eicosanoid biosynthesis play a significant role in the 
disproportionate and excessive inflammatory response characteristic of CF 
airways. Utilizing a human airway epithelial cell culture model, we found 
marked over-expression of PUFA and eicosanoid biosynthesis enzymes in 
response to an inflammatory stimulus in CF compared with control cells. This 
resulted in significantly increased production of pro-inflammatory cytokines 
that is predominantly mediated by eicosanoids of the 5-LOX pathway. These 
findings suggest a prominent role for PUFA and eicosanoid metabolism in the 
altered inflammatory response in CF. 
 
Materials and Methods 
Materials:  
NS-398 was obtained from Tocris Bioscience (Minneapolis, MN), AA-
861 from Santa Cruz (Santa Cruz, CA), docosahexaenoic acid from NuChek 
Prep (Elysian, MN), and Bacto Peptone from BD Diagnostics (Sparks, MD). 
MK-886, d4-LTB4, and rabbit monoclonal antibody for detection of human 
COX-2 were obtained from Cayman Chemicals (Ann Arbor, MI). SC-57461-A 
and mouse monoclonal antibody for detection of human β-actin were from 
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Sigma-Aldrich (St. Louis, MO). Rabbit polyclonal antibody for detection of 
human mPGES-1 and polyclonal goat anti-rabbit secondary antibody were 
from Abcam (Cambridge, MA). Rabbit monoclonal antibody for detection of 
human IL-6 was from Cell Signaling Technology (Danvers, MA) and polyclonal 
sheep anti-mouse secondary antibody was from GE Healthcare Life Sciences 
(Pittsburgh, PA). Fatty acid methyl ester (FAME) standards for HPLC were 
purchased from NuCheck Prep (Elysian, MN). HPLC grade solvents were 
purchased from Fisher Scientific (Pittsburgh, PA). Liquid scintillation cocktail 
(FlowLogic U) was purchased from LabLogic Systems, Inc. (Brandon, FL).  
 
CF Mice: 
All experiments were carried out under supervision of the Vanderbilt 
Division of Animal Care using protocols approved by the Institutional Animal 
Care and Use Committee. CFTRtm1/UNC heterozygous mice (CFTR+/-) on a 
C57BL/6J genetic background (B6.129P2-Cftrtm1Unc/J, stock number 
002196) were purchased from Jackson Laboratories (Bar Harbor, ME). These 
mice carry one copy of CFTR lacking exon 10 that encodes the first 
transmembrane domain of CFTR (CFTRTM1UNC) 173. The mice were housed 
within a specific pathogen-free barrier facility with a 12 hour light/dark cycle. 
Homozygous knockout (CF; CFTR-/-) and wild-type (WT; CFTR+/+) mice were 
generated by mating male and female heterozygotes. Tail-clip samples from 
14-day old mice were used for genotyping by PCR 174. WT and CF mice were 
weaned at approximately day 21 and subsequently maintained on a water and 
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liquid Peptamen (Nestle HealthCare Nutrition, Inc, Florham, NJ) diet for 14 
additional days. The liquid diet was used to prevent intestinal obstruction. Mice 
were euthanized with carbon dioxide and lung tissue was collected and cell 
suspension enriched for epithelial cells was generated as previously 
described120. 
  
Cell Culture:  
Human airway epithelial cells (HAEC) CuFi-1 and NuLi-1 were a kind 
gift from Dr. Simon Rousseau (McGill University, Montreal, Quebec, Canada). 
NuLi-1 (control) cells were derived from the normal airway of a 36-year-old 
healthy subject, while CuFi-1 (CF) cells were derived from the airway of a 14-
year-old patient with cystic fibrosis due to homozygous ∆F508 mutation in the 
CFTR gene 175. The cells were grown in serum-free Bronchial Epithelial 
Growth Media (BEGM) that was supplemented with BEGM Bullet Kit (Lonza), 
linoleic acid (L9530) (Sigma), and 50 µg/mL G-418 (Life Technologies), and 
maintained at 37oC in 5% CO2. The medium was changed every other day 
until 2-days post-confluence (7 days). 
Sense and antisense human bronchial epithelial cells (16HBEo-) were a 
kind gift from Dr. Pamela Davis (Case Western Reserve University School of 
Medicine, Cleveland, OH). These cells are immortalized human bronchial 
epithelial cells stably transfected with a segment of the CFTR gene in the 
sense (control) or antisense (CF) orientation 132. Control cells have normal 
CFTR expression and activity, while CF cells lack both 122,132. These cells 
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were grown in MEM + glutamax (Life Technologies) with 10% horse serum 
(Omega Scientific), penicillin (100 U/mL), and streptomycin (100 µg/mL), and 
maintained at 37oC in 5% CO2. Medium was changed every other day.  
 
Fatty Acid Supplementation:  
Docosahexaenoic acid (DHA) was added to BEGM medium that has 
been supplemented with bovine serum albumin (BSA) at a 2.5:1 BSA:DHA 
molar ratio. Control medium contained BSA only. CuFi-1 and NuLi-1 cells were 
set up on day 0 and allowed to attach for 24 hours in BEGM serum-free 
medium as described above. On day 1, cells were washed with PBS and fed 
DHA-supplemented or control medium that was changed every other day until 
confluence. 
 
Pseudomonas aeruginosa Filtrate (PaF) Stimulation:  
PaF was prepared from a stable mucoid P. aeruginosa isolate obtained 
from the lungs of a cystic fibrosis patient as described previously 176-178. 
Briefly, the bacteria were grown in 4% peptone (BD Diagnostics) at 37oC for 
72 hours with shaking at 270 RPM. The culture was then collected and 
centrifuged at 10,000 RPM for 1 hour at 4oC followed by filtration through a 
0.22 µm filter (Nalgene). The resulting filtrate was heat-inactivated at 95oC for 
10 minutes prior to use. Cells were stimulated with  20 µL PaF (equivalent to 
15 µg PaF protein) per mL of culture medium for 12 hours in the presence or 
absence of various treatments (NS-398, AA-861, MK-886, or SC-57461A). 
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After 12 hours of stimulation, the media was used for eicosanoid or cytokine 
analysis while the cells were harvested for protein or mRNA analysis. The 12 
hour time was selected because time course studies indicated maximal 
stimulation at this point (data not shown). 
 
Fatty acid composition analysis: 
 After growing for 7 days, cells were scraped on ice with a rubber 
policeman and ice-cold PBS then centrifuged at 100xg for 8 min. Pelleted cells 
were resuspended with 500 µL ice-cold PBS and 10 µg of heptadecanoic acid 
(17:0) was added as an internal standard. Lipids were then extracted 
according to the modified Folch method 134. Briefly, 3 mL of chloroform-
methanol (2:1 v/v) were added to resuspended cells and vortexed heavily. 
Samples were incubated on ice for 10 min, vortexed, then centrifuged at 
1100xg for 10 min. The resulting lower phase was dried completely under 
nitrogen in preparation for fatty acid methylation using boron trifluoride (BF3)-
methanol and a methanolic-base reagent. Briefly, 500 µL of 0.5 N methanolic 
then 500 µL NaOH BF3-methanol were added to samples. Each step was 
followed by heating at 100oC for 3 minutes then 1 minute, respectively. The 
resulting fatty acid methyl esters (FAMEs) were extracted with 1 mL hexane 
followed by 6.5 ml of saturated NaCl solution. FAMEs were identified using an 
Agilent 7980A gas chromatography (GC) system (Agilent Technologies, Santa 
Clara, CA) equipped with a Supelcowax SP-10 capillary column (Supelco, 
Bellefonte, PA) coupled to an Agilent 5975C mass spectrometer (MS). FAME 
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mass was determined by comparing areas of unknown FAMEs to that of the 
17:0 internal standard. Results were reported as the molar percentage (mol%) 
of each FAME relative to the total mass of the sample, as previously described 
133.  
 
Fatty acid radiolabeling experiments: 
On day 7, cells were incubated with media containing 10% reduced 
lipid-FCS and [1-14C]LA for 4 hours. Lipids were extracted and fatty acids were 
methylated as described above. FAMEs in the final hexane layer were 
resuspended in 50 µL acetonitrile after hexane was dried under nitrogen in 
preparation for HPLC analysis. Radiolabeled FAMEs were separated by 
reverse-phase high performance liquid chromatography (RP-HPLC) using a 
binary solvent system on an Agilent 1200 series instrument equipped with a 
(4.6 x 250 mm, 5 µm) Agilent Zorbax Eclipse XDB-C18 column and a (4.6 x 
12.5 mm, 5 µm) column guard. Solvent A consisted of H2O + 0.02% H2PO4 
and solvent B was 100% acetonitrile. The solvent program was 58% solvent B 
for 25 min, 58-61% B for 2 min, 61% B for 8 min, 61-100% B for 15 min, 100% 
B for 20 min, and finally reconstitution to original conditions. UV detection at 
205 nm and comparison with the retention times of unlabeled standards was 
used for identification of radiolabeled peaks. Quantification of the peaks was 
done by using an IN/US β-RAM Model 4 scintillation detector coupled to the 
HPLC instrument. Results were reported as percentage of total measured 
counts in a sample. 
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Eicosanoid Analysis:  
Cell culture media were collected from different treatment conditions as 
described above, and were acidified to pH 3 using 1 N HCl followed by the 
addition of 10 ng internal standard d4-LTB4. The samples were then extracted 
using 100 mg C18 Restek SPE Cartridges (Bellefonte, PA). Eicosanoids were 
eluted from the SPE cartridges with ethyl acetate followed by methanol. Eluted 
samples were dried under nitrogen and derivatized with N-(4-
aminomethylphenyl)pyridium (AMPP) that was synthesized as described 
previously 179. Derivatization was initiated by the addition of 10 µL of ice-cold 
acetonitrile/dimethylformamide (4:1 by volume) to the dried samples, then 10 
µL of ice-cold 640 mM 1-ethyl-3-(e-dimethylaminopropyl)carbodiimide. Next, 
20 µL of a freshly-prepared solution of 5 mM N-hydroxylbenzotriazole and 15 
mM AMPP dissolved in acetonitrile was added to the samples. The samples 
were vortexed, incubated for 30 minutes at 60oC, transferred to analysis vials, 
and kept on ice for LC-MS/MS analysis. Samples (20 µL) were analyzed on a 
Thermo LTQ mass spectrometer that was interfaced to an Acquity liquid 
chromatograph using a C18 column. The mobile phase consisted of solvent A 
(water:acetonitrile, 95:5 and 0.1% formic acid) and solvent B 
(water:acetonitrile 5:95 0.1% formic acid). The elution program was a linear 
gradient from A to B over 10 minutes. The electrospray needle was maintained 
at 5.03 kV and ion transfer tube operated at 31.8 V and 280oC. Transitions for 
5-HETE, LTB4, d4-LTB4, and PGE2 were recorded in the selected reaction 
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monitoring (SRM) mode as m/z 487 to 283, m/z 503.5 to 322.9, m/z 507 to 
325, and m/z 519 to 239, respectively. Since there were no significant 
differences in cellular protein concentrations, eicosanoid levels in cell culture 
media were reported as ng/mL.  
 
Cytokine Analysis:  
IL-6 and IL-8 in culture media were measured in triplicates by 
MILLIPLEX (EMD MILLIPORE, Billerica, MA) at the Vanderbilt Hormone 
Assay and Analytical Services Core.  
 
Quantitative Real-Time PCR: 
 Total RNA was isolated from cells using TRIzol (Life Technologies, 
Carlsbad, CA) and contaminating DNA was removed from samples using 
DNA-free (Ambion, Austin, TX). Complementary DNA (cDNA) was 
synthesized from 1 µg of total RNA using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA). Quantitative real-time PCR (qRT-PCR) was performed in 
10 µL reactions containing 50 ng cDNA, TaqMan primer-probes sets and 
TaqMan Universal PCR Master Mix in 96-well plates (Life Technologies, 
Carlsbad, CA). Each reaction was performed in duplicate or triplicate. Ct 
values were determined using the CFX96 Real Time PCR Detection System 
with CFX Manager software (Bio-Rad, Hercules, CA). Relative mRNA levels 
were calculated using the comparative Ct method using RPLP0 or GAPDH as 
a reference gene in cultured cells and mice tissue, respectively.  
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Immunoblot Analysis:  
Whole-cell lysates were prepared with RIPA lysis buffer (Sigma-Adrich) 
and 2X Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, 
Waltham, MA). Protein concentration was determined using BCA assay 
(Thermo Scientific). Protein samples were mixed 1:1 with 2X Laemmli Sample 
Buffer (Bio-Rad Laboratories, Hercules, CA) and stored in aliquots at -80oC. 
For electrophoresis, 15 µg of protein were run on pre-cast 4-20% 
polyacrylamide gels (Bio-Rad) and transferred to Immobilon-P PVDF 
membranes (EMD Millipore). Membranes were blocked using 5% (w/v) 
Blotting Grade Blocker (Bio-Rad) in TBS-Tween (Sigma-Aldrich). To visualize 
protein bands after primary and secondary antibody incubation, SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) was used and 
membranes were exposed to Amersham Hyperfilm ECL film (GE Healthcare). 
β-actin was used as a loading control.  
 
Statistical Analysis:  
Data was compared using t test or two-way ANOVA with Bonferroni 
post-test for pairwise comparisons as appropriate (see Figure Legends) using 
Prism 6 (GraphPad Software, La Jolla, CA). P<0.05 was considered 
statistically significant. 
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Results 
 
Increased Expression of Key Eicosanoid Biosynthetic Enzymes In CF Mice   
CFTR-/- knockout (CF) mice exhibit an increased inflammatory 
response compared to wild-type (WT) mice 120. To determine whether 
eicosanoid biosynthesis might play a role in this heightened response, the 
expression of key enzymes in the eicosanoid synthesis pathways was 
measured in the lungs of CF and WT mice. Indeed, mRNA expression of 
COX-2, 5-LOX, and mPGES-1 were all significantly elevated in CF compared 
to WT mice at baseline (Fig. 16). 
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FIGURE 16: 
Relative mRNA expression levels of eicosanoid metabolic enzymes in 
lung epithelial cells from CFTR-/- knockout (CF) and wild-type (WT) mice. 
Cell suspension enriched for epithelial cells was collected from lung tissue of 
CF and WT mice and mRNA was extracted as described in Experimental 
Procedures. Relative mRNA sequences for cyclooxygenase-2 (COX-2), 5-
lipoxygenase (5-LOX), and microsomal PGE2 synthase-1 (mPGES-1) were 
measured by qRT-PCR analysis. Relative expression was determined using 
the ΔΔCt method using GAPDH as an invariant control. Bars represent mean 
± SEM (n=7). *, P<0.05; ***, P<0.001. 
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Increased Eicosanoid Biosynthesis in CF Cells   
To determine the impact of eicosanoid biosynthesis on inflammation in 
CF, we focused on a cell culture model, using the CF HAEC line, CuFi-1, and 
the corresponding control line, NuLi-1. Inflammation was stimulated with PaF, 
a filtrate of medium in which a clinical isolate of Pseudomonas aeruginosa 
from a CF patient was cultured 176-178. In untreated CuFi-1 cells, the mRNA 
expression of Δ6D, cPLA2α, and mPGES-1 was significantly higher than in 
NuLi-1 cells (Fig. 17A). PaF stimulated a further increase in mRNA expression 
of these genes as well as COX-2 in CuFi-1 cells, while there was little or no 
change in expression in NuLi-1 cells (Fig. 17A). Corresponding protein 
expression of COX-2 was undetectable in both NuLi-1 and CuFi-1 cells at 
baseline, but there was a significant increase in CuFi-1 cells only after 
incubation with PaF. Expression of mPGES-1 protein was also significantly 
higher in CuFi-1 cells compared with NuLi-1 cells, although there was no 
apparent stimulation by PaF (Fig. 17B). To determine the effect of these 
changes on PGE2  production, PGE2 levels were measured in culture medium 
from these cells. PGE2 levels were significantly higher in medium from CuFi-1 
cells compared with that from NuLi-1 cells both at baseline and after PaF 
stimulation (Fig. 17C). PaF appeared to slightly increase PGE2 levels in CuFi-
1 cells, but the difference was not statistically significant. 
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FIGURE 17:  
Eicosanoid Biosynthesis in NuLi-1 (control) and CuFi-1 (CF) cells. A. 
Relative mRNA expression of fatty acid and eicosanoid metabolic enzymes in 
NuLi-1 (control) and CuFi-1 (CF) cells. NuLi-1 and CuFi-1 cells were cultured 
for 7 days as described in Experimental Procedures. On day 7, the cells were 
stimulated with Pseudomonas aeruginosa filtrate (PaF) for 12 hours. After 
stimulation, cells were harvested and mRNA extracted. Relative mRNA levels 
for Δ6-desaturase (Δ6-D), cytosolic phospholipase A2α (cPLA2α), 
cyclooxygenase-2 (COX-2), and microsomal PGE2 synthase-1 (mPGES-1) 
were measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. B. Protein expression of COX-2 
and mPGES-1 in NuLi-1 and CuFi-1 cells. Cells were cultured and stimulated 
with PaF as above. After stimulation, whole cell lysates were subjected to 
SDS-PAGE and immunoblotting was performed as described in Experimental 
Procedures using antibodies against COX-2 and mPGES-1. Anti-β-actin 
antibodies were used as a loading control. C. PGE2 production in NuLi-1 and 
CuFi-1 cells. Cells were cultured and stimulated as above. After stimulation, 
culture media was collected,  extracted, and derivatized as described in 
Experimental Procedures. PGE2 levels were measured by LC-MS/MS. Bars 
represent mean ± SEM (n=3). These results are representative of at least two 
independent experiments. Unlike letters indicate significant differences with 
any pair of values with at least P<0.05 by two-way ANOVA with Bonferroni 
post-test for pair-wise comparisons. 
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Expression of 5-LOX mRNA was also significantly higher in CuFi-1 cells 
compared with NuLi-1. PaF stimulation reduced 5-LOX expression in both cell 
types, although expression remained higher in the CuFi-1 cells (Fig. 18A). 
Accordingly, LTB4 levels in culture medium were higher in CuFi-1 cells at 
baseline, and declined with PaF stimulation (Fig. 18B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	  
92	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 18: 
Relative mRNA expression of 5-lipoxygenase (5-LOX) in NuLi-1 (control) 
and CuFi-1 (CF) cells. Cells were cultured for 7 days as described in 
Experimental Procedures. On day 7, the cells were stimulated with or without 
Pseudomonas aeruginosa filtrate (PaF) for 12 hours. After stimulation, cells 
were harvested and mRNA extracted. Relative mRNA levels for 5-LOX were 
measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. (B) LTB4 production in NuLi-1 
and (CF) cells. Cells were cultured and stimulated as above. After stimulation, 
culture media was collected, extracted, and derivatized as described in 
Experimental Procedures. LTB4 levels were measured by LC-MS/MS. Bars 
represent mean ± SEM (n=3). These results are representative of at least two 
independent experiments. Unlike letters indicate significant differences with 
any pair of values with at least P<0.05 by two-way ANOVA with Bonferroni 
post-test for pair-wise comparisons. 
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Cytokine Production Is Higher in CF Cells   
Interleukins IL-6 and IL-8 are thought to play an important role in 
pulmonary inflammation in CF 158,177. To determine the effect of PaF 
stimulation on the production of these cytokines, culture medium was collected 
from both cell types before and after 12 hours of PaF stimulation. IL-6 and IL-8 
levels, measured by MILLIPLEX multianalyte panel assays, were almost 
undetectable at baseline, but showed a marked increase in CuFi-1 cell 
cultures with PaF stimulation (Fig. 19A). Corresponding increases in NuLi-1 
cell cultures were much smaller and not statistically different from baseline. 
Similar changes were seen in IL-6 and IL-8 mRNA levels (Fig. 19B) and IL-6 
protein levels (Fig. 19C), indicating that these assays could be used as 
surrogates to measure production of cytokines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	  
94	  
 
 
 
 
 
 
 
 
 
 
	  	  
	  
95	  
 
 
FIGURE 19: 
Cytokine levels in NuLi-1 (control) and CuFi-1 (CF) cells. A. Cytokine 
production in NuLi-1 (control) and CuFi-1 (CF) cells. Cells were cultured for 7 
days as described in Experimental Procedures. On day 7, the cells were 
stimulated with or without Pseudomonas aeruginosa filtrate (PaF) for 12 hours. 
After stimulation, culture media was collected and IL-6 and IL-8 concentrations 
were measured by MILLIPLEX as described in Experimental Procedures. B. 
IL-6 and IL-8 mRNA expression in NuLi-1 and CuFi-1 cells. Cells were 
cultured and stimulated as above. After stimulation, mRNA was extracted and 
cDNA was synthesized as described in Experimental Procedures. Relative 
mRNA levels for IL-6 and IL-8 were measured by qRT-PCR. Relative 
expression was calculated by the ΔΔCt method using RPLP0 as an invariant 
control. C. IL-6 protein expression in NuLi-1 and CuFi-1 cells. Cells were 
cultured and stimulated as above. After stimulation, whole cell lysates were 
subjected to SDS-PAGE and immunoblotting was performed as described in 
Experimental Procedures using antibodies against IL-6. Anti-β-actin antibodies 
were used as a loading control. Bars represent mean ± SEM (n=3). These 
results are representative of at least two independent experiments. Unlike 
letters indicate significant differences with any pair of values with at least 
P<0.05 by two-way ANOVA with Bonferroni post-test for pair-wise 
comparisons. 
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Increased Expression of Eicosanoid Biosynthetic Enzymes in Another Cell 
Model   
To confirm that the changes observed in eicosanoid biosynthesis and 
cytokine production are due to the defect in CFTR, the PaF stimulation 
experiments were repeated in another respiratory epithelial cell line, 16HBEo-. 
In these cells, CFTR expression is blocked by stable transfection of plasmid 
expressing CFTR mRNA in the antisense orientation (antisense cells) 132. 
Control cells express the same mRNA, but in the sense orientation (sense 
cells), such that CFTR expression is unchanged. Similar to the results seen in 
CuFi-1 and NuLi-1 cells, mPGES-1, cPLA2α, and 5-LOX all showed 
significantly greater expression in antisense versus sense cells at baseline 
(Fig. 20B-D). COX-2 mRNA was also higher at baseline in these antisense 
cells (Fig. 20A). Incubation with PaF further stimulated COX-2 expression in 
antisense cells only (Fig. 20A), as well as mRNAs for IL-6 and IL-8 (Fig. 20E-
F). Similar to the CuFi-1 and NuLi-1 cells, PaF significantly reduced 5-LOX 
expression in antisense cells, although it remained higher than in sense cells. 
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FIGURE 20: 
Relative mRNA expression of eicosanoid metabolic enzymes and 
cytokines in 16HBEo- sense (S) and antisense (AS) cells. S cells express 
CFTR (control), while AS cells lack CFTR expression (CF). Cells were grown 
in complete medium for 7 days as described in Experimental Procedures. On 
day 7, the cells were stimulated with Pseudomonas aeruginosa filtrate (PaF) 
for 12 hours. After stimulation, mRNA was extracted and cDNA was 
synthesized as described in Experimental Procedures. Relative mRNA levels 
for cyclooxygenase-2 (COX-2), microsomal PGE2 synthase-1 (mPGES-1), 
cytosolic phospholipase A2α (cPLA2α), 5-lipoxygenase (5-LOX), IL-6, and IL-8 
were measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. Bars represent mean ± SEM 
(n=3). These results are representative of at least two independent 
experiments. Unlike letters indicate significant differences with any pair of 
values with at least P<0.05 by two-way ANOVA with Bonferroni post-test for 
pair-wise comparisons. 
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Inhibition of Eicosanoid Biosynthesis Blocks Paf-Stimulated Cytokine 
Production   
To test the hypothesis that eicosanoids drive PaF-stimulated cytokine 
production from CF cells, we stimulated CuFi-1 cells in the presence or 
absence of the COX-2 specific inhibitor NS-398 180 or the 5-LOX inhibitor AA-
861 181. Incubation with 10 µM NS-398 eliminated PGE2 production by the 
cells (Fig. 21). While inhibition of COX-2 by NS-398 had no effect on COX-2 
mRNA expression, it increased 5-LOX expression at baseline without 
changing the inhibitory effect of PaF on 5-LOX (Fig. 21). In addition, there was 
no change in IL-6 expression, but there was a small, but statistically significant 
decrease in PaF-stimulated IL-8 expression. 
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FIGURE 21: 
Effect of cyclooxygenase-2 (COX-2) inhibition by NS-398 on relative 
mRNA expression of eicosanoid metabolic enzymes and cytokines in 
CuFi-1 (CF) cells. Cells were cultured for 7 days as described in Experimental 
Procedures. On day 7, the cells were stimulated with or without Pseudomonas 
aeruginosa filtrate (PaF) for 12 hours in the presence of 10 µM NS-398 or 
equal volumes of vehicle (DMSO). After stimulation, mRNA was extracted and 
cDNA was synthesized as described in Experimental Procedures. Relative 
mRNA levels for COX-2, 5-lipoxygenase (5-LOX), IL-6, and IL-8 were 
measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. Bars represent mean ± SEM 
(n=2). These results are representative of at least two independent 
experiments. Unlike letters indicate significant differences with any pair of 
values with at least P<0.05 by two-way ANOVA with Bonferroni post-test for 
pair-wise comparisons. 
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Incubation with 10 µM AA-861 reduced LTB4 in the culture medium to 
undetectable levels (Figure 22). Inhibition of 5-LOX by AA-861 completely 
blocked the PaF-stimulated increase in COX-2 mRNA and protein expression 
(Fig. 22). Baseline 5-LOX mRNA was also reduced to levels seen after PaF 
stimulation. In addition, incubation with AA-861 completely blocked the PaF-
stimulated increase in IL-6 and IL-8 mRNA and IL-6 protein (Fig. 22). 
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FIGURE 22: 
A. Effect of 5-lipoxygenase (5-LOX) inhibition by AA-861 on relative 
mRNA expression of eicosanoid metabolic enzymes and cytokines in 
CuFi-1 cells. Cells were cultured for 7 days as described in Experimental 
Procedures. On day 7, the cells were stimulated with or without Pseudomonas 
aeruginosa filtrate (PaF) for 12 hours in the presence of 10 µM AA-861 or 
equal volumes of vehicle (ethanol). After stimulation, mRNA was extracted and 
cDNA was synthesized as described in Experimental Procedures. Relative 
mRNA levels for cyclooxygenase-2 (COX-2), 5-LOX, IL-6, and IL-8 were 
measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. Bars represent mean ± SEM 
(n=2). Unlike letters indicate significant differences with any pair of values with 
at least P<0.05 by two-way ANOVA with Bonferroni post-test for pair-wise 
comparisons. B. Effect of 5-LIOX inhibition by AA-861 on protein expression of 
COX-2 and IL-6 in CuFi-1 cells. Cells were cultured and stimulated with PaF in 
the presence of 10 µM AA-861 or vehicle (ethanol) as above. After stimulation, 
whole cell lysates were subjected to SDS-PAGE and immunoblotting was 
performed as described in Experimental Procedures using antibodies against 
COX-2 and IL-6. Anti-β-actin antibodies were used as a loading control. These 
results are representative of at least two independent experiments. 
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The 5-LOX accessory protein 5-lipoxygenase-activating protein (FLAP) 
physically interacts with 5-LOX and is essential to its enzymatic function 182. 
Thus, to confirm the role of 5-LOX in the stimulation of cytokine production, 
cells were incubated with 10 µM MK-886, a specific small molecule inhibitor of 
FLAP 183. Similar to the results seen with AA-861, incubation of CuFi-1 cells 
with MK-886 completely blocked the PaF-stimulated increases in COX-2, IL-6, 
and IL-8 mRNA expression (Fig. 23). 
Based on its role in the initiation of acute inflammation, we 
hypothesized that LTB4 was the most likely 5-LOX product to stimulate IL-6 
and IL-8 production. LTA4 hydrolase (LTA4H) catalyzes the conversion of 
LTA4, the product of 5-LOX, to LTB4 184. When CuFi-1 cells were incubated 
with 0.5 mM SC-57461A, a specific small molecular inhibitor of LTA4H 185, the 
PaF-stimulated increases in COX-2, IL-6, and IL-8 expression were completely 
abrogated (Fig. 23). 
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FIGURE 23:  
Inhibitors of 5-lipoxygenase activating protein (FLAP) and LTA4 
hydrolase (LTA4H) block PaF-stimulated increase COX-2 and cytokine 
expression in CuFi-1 cells. Cells were cultured for 7 days as described in 
Experimental Procedures. On day 7, the cells were stimulated with or without 
Pseudomonas aeruginosa filtrate (PaF) for 12 hours in the presence of either 
10 µM MK-886 (FLAP inhibitor), 0.5 mM SC-57461-A (LTA4H inhibitor) or 
equal volumes of vehicle (DMSO). After stimulation, mRNA was extracted and 
cDNA was synthesized as described in Experimental Procedures. Relative 
mRNA levels for cyclooxygenase-2 (COX-2), IL-6, and IL-8 were measured by 
qRT-PCR. Relative expression was calculated by the ΔΔCt method using 
RPLP0 as an invariant control. Bars represent mean ± SEM (n=2). These 
results are representative of at least two independent experiments. Unlike 
letters indicate significant differences with any pair of values with at least 
P<0.05 by two-way ANOVA with Bonferroni post-test for pair-wise 
comparisons. 
 
 
 
 
 
 
 
 
	  	  
	  
104	  
DHA Attenuates the Paf-Stimulated Inflammatory Response   
A prior study demonstrated that hyperreactive inflammatory response 
seen in the lungs of CFTR-/- knockout (CF) mice could be blunted by dietary 
supplementation with DHA 120. To determine whether this effect was mediated 
through the eicosanoid pathway, CuFi-1 cells were cultured for 6 days in the 
presence or absence of 20 µM DHA prior to PaF stimulation. Cells treated with 
DHA showed a significant attenuation of the PaF-stimulated increases in COX-
2, IL-6, and IL-8 mRNA (Figure 24A) and COX-2 and IL-6 protein expression 
(Fig. 24B). In addition, DHA pretreatment reduced baseline 5-LOX mRNA 
levels (Fig. 24A). 
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FIGURE 24: 
Docosahexaenoic acid (DHA) supplementation blocks PaF-stimulated 
increase COX-2 and cytokine expression in CuFi-1 cells. A. Cells were 
cultured for 24 hours in standard medium as described in Experimental 
Procedures. After 24 hours, cells were cultured in medium supplemented with 
either 20 µM DHA in a BSA:DHA 2.5:1 molar ratio or equivalent BSA 
concentrations without DHA for a total of 7 days. On day 7, the cells were 
stimulated with Pseudomonas aeruginosa filtrate (PaF) for 12 hours without 
DHA. After stimulation, mRNA was extracted and cDNA was synthesized as 
described in Experimental Procedures. Relative mRNA levels for 
cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), IL-6, and IL-8 were 
measured by qRT-PCR. Relative expression was calculated by the ΔΔCt 
method using RPLP0 as an invariant control. Bars represent mean ± SEM 
(n=2). Unlike letters indicate significant differences with any pair of values with 
at least P<0.05 by two-way ANOVA with Bonferroni post-test for pair-wise 
comparisons. B. Cells were cultured and stimulated with PaF in the presence 
of 10 µM AA-861 or vehicle (ethanol) as above. After stimulation, whole cell 
lysates were subjected to SDS-PAGE and immunoblotting was performed as 
described in Experimental Procedures using antibodies against COX-2 and IL-
6. Anti-β-actin antibodies were used as a loading control. These results are 
representative of at least three independent experiments. 
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PUFA Alterations Observed in CF Cells 
To confirm that the reported PUFA alterations are present in the HAEC 
cell line, we measured fatty acid levels by GC-MS in both CuFi-1 and NuLi-1 
cells. CuFi-1 cells exhibited the hallmark changes in the n-7 and n-9 pathways, 
where levels of 16:1n-7, 18:1n-7, and 18:1n-9 were all higher in CuFi-1 (Fig. 
25A). In the n-3 pathway, DHA levels were lower in CuFi-1 cells (Fig. 25B). 
Finally, in the n-6 pathway, CuFi-1 cells had lower levels of LA (Fig. 25C) and 
higher levels 18:3n-6, 20:3n-6, and 20:4n-6 (Fig. 25D), measured by GC-MS. 
The lower levels of LA and higher levels of its downstream products in the n-6 
pathway, correlates with the increased expression of Δ6D we saw in these 
cells (Fig. 17).  The increased metabolism from LA to AA was confirmed by 
radiolabeled studies (Fig. 26), measured by HPLC and radioactive counter. 
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FIGURE 25: 
Characteristic PUFA alterations are present in CuFi-1 cells. Fatty acid 
composition of HAECs NuLi-1 (WT) and CuFi-1 (CF) cells. WT and CF cells 
were grown in serum-free BEGM media supplemented with LA for 7 days. On 
day 7, total lipids were extracted and fatty acids were methylated. The 
resulting FAMEs were identified and quantified by GC-MS as described in 
Materials and Methods. Levels of (A.) common n-7 and n-9 fatty acids; (B.) 
22:6n-3, DHA; (C.) 18:2n-6, LA; (D.) common n-6 Fatty acids. Data are 
presented as the molar percentage (mol%) of total mass of fatty acids. Bars 
represent mean ± SEM (n=2). These results represent two independent 
experiments. ***P<0.001, **P<0.01. 
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FIGURE 26:  
Increased metabolism in the n-6 pathway in CuFi-1 cells. Metabolism of [1-
14C]LA through the n-6 pathway in HAECs NuLi-1 (WT) and CuFi-1 (CF) cells. 
WT and CF cells were grown in serum-free BEGM media supplemented with 
LA for 7 days. On day 7, cells were incubated for 4 hours with [1-14C]LA then 
chased with fresh medium for 20 hours. After that, total lipids were extracted 
and fatty acids were methylated. The resulting radiolabeled FAMEs were 
identified and quantified by HPLC coupled with a radioactive detector and 
reported as percentage of total counts (dpm) as described in Materials and 
Methods. Bars represent mean ± SEM (n=2). These results represent two 
independent experiments. ***P<0.001, *P<0.05. 
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Discussion 
 
The results described in this work draw a connection between aberrant 
fatty acid and eicosanoid biosynthesis and the hyperresponsive inflammatory 
response that is characteristic of CF pulmonary disease. First, the results 
demonstrate that CF airway epithelial cells over-express fatty acid and 
eicosanoid biosynthesis enzymes at baseline, including Δ6D, cPLA2α, COX-2, 
5-LOX, and mPGES-1, resulting in higher baseline production of PGE2 and 
LTB4 (Figs. 16,17). This expression is further induced by exposure to products 
of Pseudomonas in PaF (Figs. 17,20). These findings support an already 
abundant literature demonstrating increased expression of eicosanoid 
metabolic enzymes in CF patients and disease models 88,91,128,171,186 and 
elevated prostaglandin and leukotriene levels in patient specimens 
162,163,167,168,187,188. However, the mechanism of these changes and their impact 
on inflammation has not been previously elucidated. 
Cytokines, especially IL-6 and IL-8, are important contributors to the 
inflammatory process in CF. In particular, airway epithelial cells are an 
important source of IL-8, which is the primary chemoattractant of neutrophils in 
the CF lung 26,158. Accordingly, exposure of CF cells to PaF stimulates a 
marked increase in IL-6 and IL-8 production that is not seen in control cells 
(Figs. 19,20). The results in this report indicate that eicosanoids play a crucial 
role in the stimulated production of these cytokines. In particular, LTB4, which 
is the primary product of 5-LOX/FLAP and LTA4H, appears to be the major 
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stimulator of IL-6 and IL-8 production as evidenced by the nearly complete 
reduction of PaF-stimulated cytokine production when cells are exposed to 
inhibitors of this pathway (Figs. 22,23). Other studies have shown that this 
increase in IL-6 expression in CF cells is due to over-activation of the MAP 
kinases p38 and ERK 177. These findings are consistent in that the LTB4 
receptors BLT1 and BLT2 signal through the MAPK pathway 189-191. 
Inhibition of 5-LOX/FLAP and LTA4H in CF cells also blocks stimulation 
of COX-2 expression by PaF (Figs. 22,23), indicating that induction of COX-2 
in airway epithelial cells is also downstream of LTB4. This may be due to 
activation of the NFκB pathway, which is activated by LTB4 and induces COX-
2 expression in CF cells 88,192. This is consistent with other models of 
eicosanoid function in acute inflammation that exhibit sequential production of 
LTB4 during initiation followed by COX-2 induction and PGE2 production 193. 
The models also describe an early peak of LTB4 production, followed by a 
rapid decline 194. This may account for the reduction of 5-LOX expression and 
LTB4 production at 12 hours following PaF exposure (Fig. 18). It is important to 
note, however, that both 5-LOX expression and LTB4 production remain higher 
in CF than control cells at this time point, suggesting that there may be 
prolonged stimulation in the CF cells. Future studies examining the time 
course of this response will be required to test this hypothesis. 
PGE2 also appears to play some role, albeit minor, in cytokine 
production, as inhibition of COX-2 by NS-398 causes a slight, but significant 
reduction in IL-8 expression (Fig. 21). These data agree with a previous study 
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in a homozygous ΔF508 epithelial cell line that showed increased IL-8 release 
in response to bradykinin stimulation 195. In this model, IL-8 production was 
amplified by supplementation with either AA or PGE2, and blunted by COX 
inhibitors indomethacin and NS-398. 
These results suggest a model for the excessive stimulation of 
inflammation by airway epithelial cells in CF (Fig. 27). At baseline, the fatty 
acid and eicosanoid metabolic pathways are primed for production of LTB4. 
AA levels are higher in CF cells due to increased activity of Δ6D 128, and there 
is higher expression of cPLA2, responsible for release of AA from 
phospholipids, and 5-LOX. Thus, upon stimulus, there is a burst of LTB4, 
which stimulates COX-2, resulting in enhanced PGE2 production, and together 
they stimulate the production of IL-6 and IL-8 and the initiation of acute 
inflammation. 
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FIGURE 27: 
Model illustrating the role of fatty acid and eicosanoid metabolism in 
cytokine production in CF cells. Black arrows indicate metabolic pathways. 
Stimulatory effects are indicated by gray arrows, the thickness of which 
indicates relative degree of simulation. Gray lines indicate inhibition of various 
enzymes by DHA. LA, linoleic acid; AA, arachidonic acid, DHA, 
docosahexaenoic acid; PL, phospholipid; Δ6D, Δ6-desaturase; FLAP, 5-
lipoxygenase activating protein; 5-LOX, 5-lipoxygenase; LTA4H, LTA4 
hydrolase; COX-2, cyclooxygenase-2; mPGES-1, microsomal PGE2 synthase. 
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These results highlight the importance of the FLAP/5-LOX/LTA4H 
pathway in the initiation and maintenance of the exaggerated inflammatory 
response in CF. Consequently, this pathway could be an attractive target for 
pharmacologic intervention in CF, where inhibition of LTB4 production could 
potentially prevent the harmful effects of excessive inflammation. However, a 
clinical trial to test the effects of the leukotriene receptor BLT1 antagonist BIIL 
284 on lung disease in CF patients was terminated early due to a significant 
increase in the number of pulmonary exacerbations in patients receiving the 
drug compared to those receiving placebo 196. A follow-up study in mice 
showed that while BIIL 284 reduced pulmonary neutrophils, there was an 
increase in Pseudomonas bacteremia and associated inflammation 197. Thus, 
complete inhibition of LTB4 action might be detrimental on balance as it 
reduces the ability to combat infection. 
An alternative approach could be to target the pathway at an earlier 
step. In this study, we demonstrate that pre-incubation of CF cells with DHA 
substantially reduces PaF-stimulated COX-2 expression, as well as IL-6 and 
IL-8 production (Fig. 24). Other studies in cultured airway epithelial cells show 
that DHA decreases AA production by inhibiting the CF-associated increase in 
fatty acid desaturase expression and activity 129. In addition, DHA reduces 
expression of COX-2 and mPGES-1 through the free fatty acid receptor-4 198. 
Other studies support this approach. Freedman et al. 120 showed that dietary 
DHA supplementation in a CF mouse model normalized the pulmonary 
inflammatory response to Pseudomonas lipopolysaccharide. This was 
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accompanied by a significant decrease in eicosanoids, particularly the 
prostaglandins PGE2, PGF2α, and 6-keto-PGF1α 199. In addition, several clinical 
trials in CF patients have shown that supplementation with n-3 fatty acids, 
including DHA, modulates leukotriene production110,200,201. Importantly, this 
supplementation did not result in significant adverse effects202. 
These results may also have dietary implications. Due to 
malabsorption, CF patients are treated with high-fat diets. Unfortunately, the 
modern western diet is enriched in n-6 fatty acids, such as LA, to a much 
greater extent than historical norms 143. In CF cells, higher levels of LA input 
contribute to excessive AA production 156. This contributes to increased 
eicosanoid and IL-8 production in LA-supplemented CF cells and increased 
pulmonary inflammation in CF mouse models 130. Thus, a diet lower in n-6 and 
higher in n-3 fatty acids might be beneficial for CF patients. 
This study has a few limitations. First, all comparisons were made 
between baseline and a single time point after stimulation. That time point was 
selected based on preliminary time course studies that indicated maximum 
COX-2 and cytokine stimulation (data not shown). However, inflammation is a 
dynamic process, so additional studies will be required to better understand 
the precise interaction between eicosanoids, cytokines, and the underlying 
molecular mechanisms that regulate them. Second, eicosanoid measurements 
were made in total cell culture medium. As they are expected to act in an 
autocrine and/or paracrine fashion, these data may not reflect the actual local 
concentrations at and between cells. Third, the primary cell culture model used 
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here involves cells from two different individuals, one with CF and one healthy 
175. Thus, it is possible that differences in genetic background could account 
for some of the changes observed. However, this concern is mitigated by 
confirmation of many of the observed differences in another cell culture model 
where the CF and control cells share the same genetic background (Fig. 20).  
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CHAPTER V 
 
DISCUSSION AND FUTURE WORK 
 
Summary 
The studies presented in this document demonstrate our work on the 
role of PUFA alterations and eicosanoid production in the inflammatory 
response in CF. We have shown that there is increased uptake and release of 
AA in CF cells. Moreover, we have demonstrated that there are changes in 
eicosanoid biosynthesis in CF airway epithelial cells compared with normal 
controls resulting in increased production of at least LTB4 and PGE2. 
Furthermore, we have revealed that eicosanoid biosynthesis, in particular the 
LTB4 pathway, plays a crucial role in the marked overproduction of pro-
inflammatory cytokines in CF cells. Lastly, we have illustrated that inhibition of 
eicosanoid biosynthesis with small molecule inhibitors, but also with DHA, can 
abrogate this excessive cytokine production. These results not only shed light 
on the mechanisms of hyperactive inflammation in CF, but they also highlight 
potential therapeutic targets and approaches that could be used to better treat 
patients with CF. 
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Future Studies 
 Our work demonstrated that PUFA alterations are part of an intrinsic 
defect in CF that contributes to the inflammatory response by excessive 
production of AA and its oxygenated metabolites. Our results in chapter IV 
clearly showed that products of the 5-LOX pathway, particularly LTB4, drive 
the exaggerated COX-2 pathway and cytokine production observed in CF 
airway epithelial cells. However, since inflammation is a dynamic process, 
further studies, both in vitro and in vivo, are required to elucidate the role of 
various cell types and their PUFA-derived oxygenated metabolites in the 
dysregulated inflammation in CF.  
 We hypothesize that the high LTB4 production levels by CF airway 
epithelial cells in chapter IV leads to the amplified neutrophil recruitment 
observed in the CF airway. Thus, we anticipate neutrophils to show higher 
chemotaxis response to media collected from CF airway epithelial cells, when 
performing in vitro chemotaxis assays. While this will implicate the airway 
epithelium as a major source of LTB4 that leads to neutrophil recruitment, 
there may be defects in CF neutrophils that lead to their excessive response. 
This concept can be tested in a variety of ways. First, neutrophil chemotaxis 
assays can be repeated with both CF and WT neutrophils, to measure any 
difference in the response of CF neutrophils to chemoattractant signals, such 
as LTB4. There have been studies that suggest a defect in the inflammatory 
response and a possible dysregulation in oxygenated metabolite production in 
CF neutrophils. Bravo et al. reported that CF neutrophils have impaired PUFA 
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release203, while Xiao et al. demonstrated that reconstitution with ΔF508 
neutrophils in WT mice lead to more severe LPS-induced lung inflammation 
and injury204. To assess whether eicosanoid production plays a role in the 
dysregulated neutrophilic inflammatory response, studies that examine 
expression and activity of both COX-2 and 5-LOX pathways should be 
performed on CF neutrophils. These studies may show an increase in 
production of pro-inflammatory eicosanoids, especially LTB4, in CF 
neutrophils. Moreover, they may also uncover other dysregulated pathways in 
these leukocytes, such as eicosanoid signaling. In particular, higher 
expression or signaling through LTB4 receptors BLT1 and BLT2 in CF 
neutrophils may contribute to their increased recruitment in CF.  
The interaction between airway epithelial cells and neutrophils affects 
eicosanoid production pathways in both cell types and drives several 
inflammatory events. In vitro production of some oxygenated metabolites, such 
as LXA4, may only occur in a co-culture model that mimics this interaction. 
LXA4 is a well-known pro-resolving mediator that can be produced via the 
combined action of two lipoxygenase enzymes derived from airway epithelial 
cells and neutrophils205. We hypothesize that the decrease in LXA4, observed 
in CF95, is due to defective “class-switching” events in the CF airway, which 
contributes to the unrelenting inflammatory response. Therefore, assessing 
this interaction in response to stimulation in a co-culture model of airway 
epithelial cells and neutrophils will further enhance our understanding of the 
role of PUFA-derived oxygenated metabolites in the pathophysiology of CF 
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lung disease. PGE2 can effectively switch the production of AA-derived 
eicosanoids from pro-inflammatory to pro-resolving by modulating the 
expression of LOX enzymes to stop LTB4 production while inducing LXA4 
production. If CF neutrophils have elevated LTB4 production, it is plausible that 
PGE2-signaling in these leukocytes may be defective. Therefore, CF 
neutrophils continue producing LTB4 instead of switching to LXA4, which leads 
to non-resolving inflammation phenotype. To elucidate this non-resolving 
phenotype, the production and signaling of n-3—derived pro-resolving 
mediators should be investigated in both neutrophils and airway epithelial cells 
in CF.   
Even though the proposed studies above will aid in characterizing role 
of airway epithelial cells and neutrophils, inflammation is a complex process 
with many contributing factors that cannot be completely recapitulated in vitro. 
Therefore, an in vivo model is necessary to truly understand the role of PUFA-
derived oxygenated metabolites in the dysregulated inflammatory response in 
CF. Mouse models are the most widely used animal models in CF. While 
these models have greatly helped in elucidating many facets of the disease, 
they are poor surrogates for pulmonary studies as they do not have 
pronounced lung disease22. A group from the University of Iowa has recently 
developed a ΔF508 pig model of CF that develops features typical of human 
disease. In particular, CF pigs develop, very early in life, spontaneous lung 
disease that is characterized by airway obstruction, infection, and 
inflammation206. This will provide a valuable system to investigate the onset of 
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inflammation in the lungs of CF pigs and assess the role of PUFA-derived 
oxygenated metabolites in the development of lung disease.   
We demonstrated in chapter IV that inhibition of the 5-LOX pathway 
was able to attenuate the inflammatory response in CF airway epithelial cells. 
The next step would be to evaluate the effect of this attenuation on neutrophil 
recruitment both in vivo and in vitro. To test this, neutrophil chemotaxis and 
co-culture assays should be repeated with inhibition of the 5-LOX pathway in 
airway epithelial cells, neutrophils, or both cell types. This will clarify whether 
the overly active 5-LOX pathway in airway epithelial cells is the main cause for 
the increased neutrophil recruitment, or that both cell types are involved in this 
dysregulation. The role of the 5-LOX pathway in the excessive inflammatory 
response can be further elucidated by pharmacologically inhibiting this 
pathway in a ΔF508 pig model, and monitoring the inflammatory response in 
these animals. Specifically, assessing neutrophil recruitment and measuring 
the generation of inflammatory mediators, such as cytokines and PUFA-
derived metabolites. Alternatively, the development of a (ALOX5-/-/ΔF508) pig 
model may elucidate the role of 5-LOX in CF more precisely.  
Due to its potency as a neutrophil chemattractant, LTB4 has been 
thought to play significant role in CF airway inflammation. A recent clinical 
study investigated this role by administering a specific BLT inhibitor (BIIL 284) 
to CF patients, and monitoring pulmonary function207. However, this study had 
to be terminated early due to increased pulmonary exacerbations. A follow-up 
study aiming to examine the cause of the increased exacerbations, 
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demonstrated a decrease in pulmonary neutrophil count and an increase in 
Pseudomonas aeruginosa bacterial load in the lungs and circulation of mice 
treated with BIIL 284 compared to their matched controls208. These studies 
demonstrate the significant role of LTB4 in the inflammatory response and 
bacterial clearance. Moreover, the results suggest that inhibiting the 5-LOX 
pathway to a level that only decreases the inflammatory response rather than 
completely inhibiting that response may yield better therapeutic benefits for CF 
patients. Therefore, we hypothesize that normalizing LTB4 production in CF 
airways, using lower doses of pharmacological inhibitors of the 5-LOX 
pathway, will result in an inflammatory response sufficient to combat bacterial 
infections but will not lead to excessive neutrophilic inflammation. This can be 
tested by performing dose response studies using inhibitors of the 5-LOX 
pathway, such as AA861, in the ΔF508 CF pig model.  
Our work showed that DHA supplementation had a significant inhibitory 
effect on the inflammatory response in CF airway epithelial cells. As 
demonstrated in chapter IV, DHA attenuated the expression of both COX-2 
and 5-LOX enzymes in CF cells. DHA may also affect the inflammatory 
response through other mechanisms. It may decrease the production of pro-
inflammatory AA-derived eicosanoids via inhibition of Δ6D97, or by replacing 
AA in phospholipids. Alternatively, DHA may exert its effect through the 
conversion to its anti-inflammatory oxygenated metabolites209. The fact that 
DHA levels are low in CF, and that decreased resolvin levels have been 
associated with poorer pulmonary function in CF patients210, may partly 
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explain the beneficial effects of DHA in CF. The effect of DHA should be 
evaluated on the production oxygenated metabolites, neutrophil function, and 
inflammatory response using both in vitro and in vivo studies, similar to the 
studies proposed for 5-LOX inhibition. It will be interesting to determine 
whether combining DHA with pharmacological inhibitors of the 5-LOX pathway 
will give the same beneficial effects, but with lower doses.     
 
Significance 
Mechanistic Connection of PUFA Alterations in CF to Disease Pathology  
 The work presented in this document provides a novel mechanism that 
connects the observed PUFA alterations in CF to disease pathophysiology. 
Herein we demonstrate that low levels of LA and increased production and 
availability of AA contribute to the excessive inflammatory response in CF via 
the production of pro-inflammatory eicosanoids. In particular, products of the 
5-LOX pathway, namely LTB4, are responsible for driving the excessive 
production of both PGE2 and inflammatory cytokines IL-6 and IL-8. This 
suggests that these PUFA alterations are essential in driving the increased 
neutrophilic inflammation in the airways of CF patients by the increased 
production of the powerful chemoattractant LTB4.  
 
Nutritional Modification  
To avoid malabsorption and malnutrition, it is recommended that CF 
patients intake a high-calorie, high-fat diet12,14. However, there are no 
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guidelines regarding the type of fat in CF diets. This leads to CF patients 
consuming large amounts of n-6 PUFA, LA in particular, due to the high n-6/n-
3 ratio in typical western diets36. Previous work from our group has shown that 
there is an increased metabolism from LA to AA in CF cells71. Moreover, as 
we demonstrated in chapter II, the increased production of AA in CF cells is 
more pronounced when LA/LNA ratio is higher. This increase in AA levels can 
further increase inflammation in CF. In support of this, Zaman et al. 
demonstrated that LA supplementation in CF cells and mice caused a 
significant increase in AA-derived eicosanoids, and increased cytokine 
production and neutrophilic inflammation136. This identifies the need for 
modification of the nutritional recommendations to increase the ratio of n-6/n-3 
PUFA by both decreasing n-6 PUFA intake while increasing n-3 PUFA 
supplementation. 
 
Therapeutic Potential  
 Significant improvements in CF treatments over the past 3 decades 
have led to an increase in median survival age among patients. Treatments in 
CF mainly deal with nutritional and pulmonary management. Nutritional 
management is designed to combat pancreatic insufficiency and 
malabsorption; patients are given pancreatic enzyme replacements and fat-
soluble vitamin supplements combined with recommendation of a high-calorie, 
high-fat diet2,7,211. Pulmonary management is based on antibiotic therapy to 
fight chronic infections, and chest physiotherapy to aid in mucus clearance2. 
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The presence of excessive non-resolving inflammation leads to tissue 
destruction, and therefore is considered as a therapeutic target. To this end, 
the effects of high-dose ibuprofen have been studies in two large clinical trials. 
Konstan et al. demonstrated that when taken for 4 years, high-dose was able 
to decrease the rate of lung function decline without any adverse effects212. 
Another study showed that ibuprofen had no effect on forced expiratory 
volume in 1 second (FEV1), although patients on ibuprofen spent fewer days in 
the hospital213. This is in line with our COX-2 inhibition findings in chapter IV, 
where inhibition of this pathway caused a slight decrease in IL-8 expression, 
and may explain the small benefits of ibuprofen in CF. Even though high-dose 
ibuprofen did not cause harmful effects in these studies, this non-selective 
COX inhibitor can potentially cause harmful side effects when taken for 
prolonged periods. This was demonstrated by a retrospective study, which 
demonstrated that many patients had to discontinue high-dose ibuprofen 
treatment due to GI side effects214. Therefore, there is a need for the 
development of safer, more potent anti-inflammatory treatments.     
An important application of our work is the development an adjuvant 
therapy for CF lung disease, which can be tested in a clinical trial. The 
therapeutic basis of this trial is a combination of DHA supplementation and 5-
LOX inhibition by AA-861. Doses of both treatments will be determined based 
on the results of our proposed in vitro and in vivo studies, outlined above. 
These studies will establish the lowest combined concentrations of DHA and 
AA-861 that can attenuate the excessive inflammatory response, but will not 
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hinder effective bacterial clearance. To avoid reaching inconclusive results, 
the proposed clinical study must follow the guidelines described next. A large 
number of CF patients must be recruited at an early age, prior to the decline in 
pulmonary function. Moreover, the study must be placebo controlled and long 
enough to assess the therapeutic effects on the development and progression 
of lung disease. In addition, special attention must be given to the nutritional 
aspect of the study, especially keeping n-6/n-3 ratio as close to 1:1 as 
possible. The outcome of the study can be determined by a variety of clinical 
markers and pulmonary function tests. For example, the levels of cytokines, 
PUFA, and PUFA-derived oxygenated metabolites may be used as markers of 
clinical status. These markers can be measured in various tissues, such as 
exhaled breath condensate, sputum, plasma, and urine.  
  
Biomarker Development 
Finally, CF patients are often faced with intermittent episodes of acute 
exacerbation of their pulmonary symptoms215. These episodes must be treated 
aggressively with antibiotic therapy, whilst increasing airway clearance 
techniques, and improving nutrition7. Even with these aggressive treatments, 
experiencing pulmonary exacerbations usually leads to a long-term decline in 
lung function and a decrease in survival rate216. Therefore, being able to 
identify the risk of having a pulmonary exacerbation flare prior to its 
occurrence, will lead to improved pulmonary outcomes and even extend life 
expectancy in CF patients217. A significant outcome of the proposed clinical 
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study, described above, could be the identification of new markers of 
pulmonary exacerbation. Measurement of the aforementioned clinical markers 
during the clinical study will provide enough data points to predict possible 
patterns of production that occur during the course of disease development, 
including exacerbations. In support of this, Wojewodka et al. demonstrated a 
correlation between certain inflammatory markers and the probability of re-
exacerbation in CF patients217. In our study we may find that, for example, an 
increase in the ratio of LTB4/LXA4 or AA/DHA is predictive of a pulmonary 
exacerbation episode. This can be utilized to monitor the clinical status of 
patients, and prompt their hospitalization when these markers are elevated to 
prevent the development of a pulmonary exacerbation flare.  
  
Closing 
 Cystic fibrosis remains a devastating disease that causes the death of 
young adults. Therefore, a better understanding of CF pathophysiology will 
lead to the development of better therapies and improvement in the quality of 
life of CF patients. These studies shed light onto the role of altered PUFA and 
eicosanoid production abnormalities in CF pathophysiology, particularly in the 
development of excessive airway inflammation.        
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